

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
Please do not report the images to the
Image Problem Mailbox.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 15/12, A01K 67/027, A61K 31/70, A61K 38/17, A61K 48/00, C07K 14/72, C07K 16/28, C12N 15/11, C12Q 1/68, G01N 33/566		A1	(11) International Publication Number: WO 00/32774 (43) International Publication Date: 08 June 2000 (08.06.2000)
(21) International Application Number: PCT/US99/28090 (22) International Filing Date: 24 November 1999 (24.11.1999) (30) Priority Data: 09/200,302 25 November 1998 (25.11.1998) US		Published	
(60) Parent Application or Grant MILLENNIUM PHARMACEUTICALS, INC. [/]; (O) GLUCKSMANN, Maria, Alexandra [/]; (O) CHUN, Myoung [/]; (O) GLUCKSMANN, Maria, Alexandra [/]; (O) CHUN, Myoung [/]; (O) SPRUILL, Murray, W. ; (O)			
(54) Title: 12216 RECEPTOR, A G-PROTEIN COUPLED RECEPTOR (54) Titre: RECEPTEUR 12216: RECEPTEUR COUPLE A LA PROTEINE G			
(57) Abstract <p>The present invention relates to a receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.</p>			
(57) Abrégé <p>La présente invention se rapporte à un récepteur appartenant à la superfamille des récepteurs couplés à la protéine G, et à des polynucléotides codant ledit récepteur. Elle se rapporte aussi à des méthodes qui mettent en oeuvre les polypeptides et les polynucléotides du récepteur en tant que cibles destinés à diagnostiquer ou traiter des troubles liés à la présence du récepteur. L'invention se rapporte également à des méthodes de criblage utilisant les polypeptides et les polynucléotides du récepteur pour identifier des agonistes et des antagonistes à des fins de diagnostic ou de traitement. L'invention se rapporte en outre à des agonistes et des antagonistes basés sur les polypeptides et les polynucléotides du récepteur. Elle se rapporte enfin à des procédés de production des polypeptides et polynucléotides du récepteur.</p>			

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/72, 16/28, G01N 33/566, C12Q 1/68, C12N 15/11, A61K 38/17, 31/70, 48/00, A01K 67/027		A1	(11) International Publication Number: WO 00/32774
			(43) International Publication Date: 8 June 2000 (08.06.00)
<p>(21) International Application Number: PCT/US99/28090</p> <p>(22) International Filing Date: 24 November 1999 (24.11.99)</p> <p>(30) Priority Data: 09/200,302 25 November 1998 (25.11.98) US Not furnished 24 November 1999 (24.11.99) US</p> <p>(71) Applicant (for all designated States except US): MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GLUCKSMANN, Maria, Alexandra [AR/US]; 33 Summit Road, Lexington, MA 02173 (US). CHUN, Myoung [US/US]; 88 Country Club Lane, Belmont, MA 02478 (US).</p> <p>(74) Agents: SPRUILL, Murray, W. et al.; Alston & Bird LLP, P.O. Drawer 34009, Charlotte, NC 28234-4009 (US).</p>			(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
<p>Published</p> <p><i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
<p>(54) Title: 12216 RECEPTOR, A G-PROTEIN COUPLED RECEPTOR</p> <p>(57) Abstract</p> <p>The present invention relates to a receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

THIS PAGE BLANK (USPTO)

25

30

35

40

45

50

55

5

12216 RECEPTOR, A G-PROTEIN COUPLED RECEPTOR

10

FIELD OF THE INVENTION

15 The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated and related disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and

20

25

30

35

40

45

50

55

10 polynucleotides.

BACKGROUND OF THE INVENTION

30 G-protein coupled receptors

15 G-protein coupled receptors (GPCRs) constitute a major class of proteins responsible for transducing a signal within a cell. GPCRs have three structural domains: an amino terminal extracellular domain, a transmembrane domain containing seven transmembrane segments, three extracellular loops, and three intracellular loops, and a carboxy terminal intracellular domain. Upon binding of a ligand to an extracellular portion of a GPCR, a signal is transduced within the cell that results in a change in a biological or physiological property of the cell. GPCRs, along with G-proteins and effectors (intracellular enzymes and channels modulated by G-proteins), are the components of a modular signaling system that connects the state of intracellular second messengers to extracellular inputs.

20

25

30

35

40

45

50

55

25 GPCR genes and gene-products are potential causative agents of disease (Spiegel *et al.*, *J. Clin. Invest.* 92:1119-1125 (1993); McKusick *et al.*, *J. Med. Genet.* 30:1-26 (1993)). Specific defects in the rhodopsin gene and the V2 vasopressin receptor gene

5 have been shown to cause various forms of retinitis pigmentosum (Nathans *et al.*, *Annu. Rev. Genet.* 26:403-424(1992)), and nephrogenic diabetes insipidus (Holtzman *et al.*, *Hum. Mol. Genet.* 2:1201-1204 (1993)). These receptors are of critical importance to both the central nervous system and peripheral physiological processes. Evolutionary
10 analyses suggest that the ancestor of these proteins originally developed in concert with complex body plans and nervous systems.

15 The GPCR protein superfamily can be divided into five families: Family I, receptors typified by rhodopsin and the β 2-adrenergic receptor and currently represented by over 200 unique members (Dohlman *et al.*, *Annu. Rev. Biochem.* 60:653-688 (1991));
20 Family II, the parathyroid hormone/calcitonin/secretin receptor family (Juppner *et al.*, *Science* 254:1024-1026 (1991); Lin *et al.*, *Science* 254:1022-1024 (1991)); Family III, the metabotropic glutamate receptor family (Nakanishi, *Science* 258 597:603 (1992)); Family IV, the cAMP receptor family, important in the chemotaxis and development of *D. discoideum* (Klein *et al.*, *Science* 241:1467-1472 (1988)); and Family V, the fungal
25 mating pheromone receptors such as STE2 (Kurjan, *Annu. Rev. Biochem.* 61:1097-1129 (1992)).

30 There are also a small number of other proteins which present seven putative hydrophobic segments and appear to be unrelated to GPCRs; they have not been shown to couple to G-proteins. *Drosophila* expresses a photoreceptor-specific protein, bride of
35 sevenless (boss), a seven-transmembrane-segment protein which has been extensively studied and does not show evidence of being a GPCR (Hart *et al.*, *Proc. Natl. Acad. Sci. USA* 90:5047-5051 (1993)). The gene *frizzled* (fz) in *Drosophila* is also thought to be a protein with seven transmembrane segments. Like boss, fz has not been shown to couple to G-proteins (Vinson *et al.*, *Nature* 338:263-264 (1989)).

40 25 G proteins represent a family of heterotrimeric proteins composed of α , β and γ subunits, that bind guanine nucleotides. These proteins are usually linked to cell surface receptors, e.g., receptors containing seven transmembrane segments. Following ligand binding to the GPCR, a conformational change is transmitted to the G protein, which causes the α -subunit to exchange a bound GDP molecule for a GTP molecule and to
45 30 dissociate from the $\beta\gamma$ -subunits. The GTP-bound form of the α -subunit typically functions as an effector-modulating moiety, leading to the production of second messengers, such as cAMP (e.g., by activation of adenyl cyclase), diacylglycerol or inositol phosphates. Greater than 20 different types of α -subunits are known in humans.

These subunits associate with a smaller pool of β and γ subunits. Examples of mammalian G proteins include Gi, Go, Gq, Gs and Gt. G proteins are described extensively in Lodish *et al.*, *Molecular Cell Biology*, (Scientific American Books Inc., New York, N.Y., 1995), the contents of which are incorporated herein by reference.

5 GPCRs, G proteins and G protein-linked effector and second messenger systems have
been reviewed in *The G-Protein Linked Receptor Fact Book*, Watson *et al.*, eds.,
Academic Press (1994).

GPCRs are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize

10 previously unknown GPCRs. The present invention advances the state of the art by providing a previously unidentified human GPCR.

SUMMARY OF THE INVENTION

5 It is an object of the invention to identify novel GPCRs.

It is a further object of the invention to provide novel GPCR polypeptides that are useful as reagents or targets in receptor assays applicable to treatment and diagnosis of GPCR-mediated disorders.

It is a further object of the invention to provide polynucleotides corresponding to

20 the novel GPCR receptor polypeptides that are useful as targets and reagents in receptor assays applicable to treatment and diagnosis of GPCR-mediated disorders and useful for producing novel receptor polypeptides by recombinant methods.

A specific object of the invention is to identify compounds that act as agonists and antagonists and modulate the expression of the novel receptor.

25 A further specific object of the invention is to provide compounds that modulate expression of the receptor for treatment and diagnosis of GPCR- related disorders.

The invention is thus based on the identification of a novel GPCR, designated the 12216 receptor.

The invention provides isolated 12216 receptor polypeptides including a polypeptide having the amino acid sequence shown in SEQ ID NO 1.

The invention also provides isolated 12216 receptor nucleic acid molecules having the sequence shown in SEQ ID NO 2.

5 The invention also provides variant polypeptides having an amino acid sequence that is substantially homologous to the amino acid sequence shown in SEQ ID NO 1.

10 The invention also provides variant nucleic acid sequences that are substantially homologous to the nucleotide sequence shown in SEQ ID NO 2.

15 5 The invention also provides fragments of the polypeptide shown in SEQ ID NO 1 and nucleotide shown in SEQ ID NO 2, as well as substantially homologous fragments of the polypeptide or nucleic acid.

20 10 The invention further provides nucleic acid constructs comprising the nucleic acid molecules described above. In a preferred embodiment, the nucleic acid molecules of the invention are operatively linked to a regulatory sequence.

25 15 The invention also provides vectors and host cells for expressing the receptor nucleic acid molecules and polypeptides and particularly recombinant vectors and host cells.

30 20 The invention also provides methods of making the vectors and host cells and methods for using them to produce the receptor nucleic acid molecules and polypeptides.

35 25 The invention also provides antibodies or antigen-binding fragments thereof that selectively bind the receptor polypeptides and fragments.

40 30 The invention also provides methods of screening for compounds that modulate expression or activity of the receptor polypeptides or nucleic acid (RNA or DNA).

35 35 The invention also provides a process for modulating receptor polypeptide or nucleic acid expression or activity, especially using the screened compounds.

40 40 Modulation may be used to treat conditions related to aberrant activity or expression of the receptor polypeptides or nucleic acids.

45 45 The invention also provides assays for determining the presence or absence of and level of the receptor polypeptides or nucleic acid molecules in a biological sample, including for disease diagnosis.

50 50 The invention also provides assays for determining the presence of a mutation in the receptor polypeptides or nucleic acid molecules, including for disease diagnosis.

55 55 In still a further embodiment, the invention provides a computer readable means containing the nucleotide and/or amino acid sequences of the nucleic acids and polypeptides of the invention, respectively.

5

DESCRIPTION OF THE DRAWINGS

10 **Figure 1** shows an analysis of the 12216 amino acid sequence: $\alpha\beta$ turn and coil regions; hydrophilicity; amphipathic regions; flexible regions; antigenic index; and surface probability plot.

15 **Figure 2** shows a 12216 receptor hydrophobicity plot. The amino acids 10 correspond to 1-373 and show the seven transmembrane segments.

20 **Figure 3** shows an analysis of the 12216 open reading frame for amino acids corresponding to specific functional sites. The protein is predicted to contain three N-glycosylation sites, from about amino acid 3 to about amino acid 6, from about amino acid 184 to about amino acid 187, and from about amino acid 229 to about amino acid 232. The protein is predicted to contain a cyclic AMP/cyclic GMP-dependent protein kinase phosphorylation site at about amino acids 133 to about amino acids 136. The protein is predicted to contain four protein kinase C phosphorylation sites, at about amino acid 82 to about amino acid 84, from about amino acid 95 to about amino acid 97, 25 from about amino acid 164 to about amino acid 166, and from about amino acid 269 to about amino acid 271. The protein is predicted to contain a casein kinase II phosphorylation site at about amino acid 4 to about amino acid 7. The protein is predicted to contain five N-myristylation sites, from about amino acid 30 to about 30 amino acid 35, from about amino acid 69 to about amino acid 74, from about amino acid 86 to about amino acid 91, from about amino acid 239 to about amino acid 244, and from about amino acid 260 to about amino acid 265. Finally, the protein is also predicted to contain a prenylation site (prenyl group binding site/CAAX box) at about 35 amino acid 371 to about amino acid 374. In addition, amino acids corresponding in position to the GPCR signature and containing the invariant arginine are found in the 40 sequence TRY at amino acids 120-122.

45 It is predicted that amino acids 1-25 constitute the amino terminal extracellular domain, amino acids 26-343 constitute the region spanning the transmembrane domain, and amino acids 344-373 constitute the carboxy terminal intracellular domain. The 50

5 transmembrane domain contains seven transmembrane segments, three extracellular loops and three intracellular loops. The transmembrane segments are found from about amino acid 26 to about amino acid 48, from about amino acid 59 to about amino acid 83, from about amino acid 98 to about amino acid 119, from about amino acid 137 to about 10 amino acid 156, from about amino acid 187 to about amino acid 204, from about amino acid 287 to about amino acid 308, and from about amino acid 321 to about amino acid 343. Within the region spanning the entire transmembrane domain are three intracellular and three extracellular loops. The three intracellular loops are found from about amino 15 acid 49 to about amino acid 58, from about amino acid 120 to about amino acid 136, and 20 from about amino acid 205 to about amino acid 286. The three extracellular loops are found at from about amino acid 84 to about amino acid 97, from about amino acid 157 to about amino acid 186, and from about amino acid 309 to about amino acid 320.

25 The transmembrane domain includes a GPCR signal transduction signature, TRY, at residues 120-122. The sequence includes an arginine at residue 121, an invariant amino acid in GPCRs. Figure 4 shows the transmembrane segments for the presumed mature peptide. Accordingly, the disclosure regarding amino acids that correspond to the amino terminal extracellular domain, the entire transmembrane domain, any of the extracellular or intracellular loops, and any of the transmembrane regions would also be understood to pertain to the specific segments shown in this figure.

30

35 **Figure 4** shows the predicted transmembrane segment configuration for the presumed mature peptide.

25 **Figure 5 shows expression of the 12216 receptor in various normal human tissues, cells, and cell lines**

Figure 6 shows expression of the 12216 receptor in various human normal and diseased cardiovascular tissues.

Figure 7 shows expression of the 12216 receptor in monkey cardiovascular

5

DETAILED DESCRIPTION OF THE INVENTION

Receptor function/signal pathway

The response mediated by the receptor protein depends on the type of cell. For example, in some cells, binding of a ligand to the receptor protein may stimulate an activity such as release of compounds, gating of a channel, cellular adhesion, migration, differentiation, etc., through phosphatidylinositol or cyclic AMP metabolism and turnover while in other cells, the binding of the ligand will produce a different result. Regardless of the cellular activity/response modulated by the receptor protein, it is universal that the protein is a GPCR and interacts with G proteins to produce one or more secondary signals, in a variety of intracellular signal transduction pathways, e.g., through phosphatidylinositol or cyclic AMP metabolism and turnover, in a cell.

45 30 As used herein, "phosphatidylinositol turnover and metabolism" refers to the molecules involved in the turnover and metabolism of phosphatidylinositol 4,5-bisphosphate (PIP₂) as well as to the activities of these molecules. PIP₂ is a phospholipid found in the cytosolic leaflet of the plasma membrane. Binding of ligand to the receptor

activates, in some cells, the plasma-membrane enzyme phospholipase C that in turn can hydrolyze PIP₂ to produce 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP₃). Once formed IP₃ can diffuse to the endoplasmic reticulum surface where it can bind an IP₃ receptor, e.g., a calcium channel protein containing an IP₃ binding site. IP₃ binding can induce opening of the channel, allowing calcium ions to be released into the cytoplasm. IP₃ can also be phosphorylated by a specific kinase to form inositol 1,3,4,5-tetraphosphate (IP₄), a molecule which can cause calcium entry into the cytoplasm from the extracellular medium. IP₃ and IP₄ can subsequently be hydrolyzed very rapidly to the inactive products inositol 1,4-biphosphate (IP₂) and inositol 1,3,4-triphosphate, respectively. These inactive products can be recycled by the cell to synthesize PIP₂. The other second messenger produced by the hydrolysis of PIP₂, namely 1,2-diacylglycerol (DAG), remains in the cell membrane where it can serve to activate the enzyme protein kinase C. Protein kinase C is usually found soluble in the cytoplasm of the cell, but upon an increase in the intracellular calcium concentration, this enzyme can move to the plasma membrane where it can be activated by DAG. The activation of protein kinase C in different cells results in various cellular responses such as the phosphorylation of glycogen synthase, or the phosphorylation of various transcription factors, e.g., NF- κ B. The language "phosphatidylinositol activity", as used herein, refers to an activity of PIP₂ or one of its metabolites.

Another signaling pathway in which the receptor may participate is the cAMP turnover pathway. As used herein, "cyclic AMP turnover and metabolism" refers to the molecules involved in the turnover and metabolism of cyclic AMP (cAMP) as well as to the activities of these molecules. Cyclic AMP is a second messenger produced in response to ligand-induced stimulation of certain G protein coupled receptors. In the cAMP signaling pathway, binding of a ligand to a GPCR can lead to the activation of the enzyme adenyl cyclase, which catalyzes the synthesis of cAMP. The newly synthesized cAMP can in turn activate a cAMP-dependent protein kinase. This activated kinase can phosphorylate a voltage-gated potassium channel protein, or an associated protein, and lead to the inability of the potassium channel to open during an action potential. The inability of the potassium channel to open results in a decrease in the outward flow of potassium, which normally repolarizes the membrane of a neuron, leading to prolonged membrane depolarization.

Polypeptides

The invention is based on the discovery of a novel G-coupled protein receptor. Specifically, an expressed sequence tag (EST) was selected based on homology to G-protein-coupled receptor sequences. This EST was used to design primers based on sequences that it contains and used to identify a cDNA from a prostate fibroblast cDNA library. Positive clones were sequenced and the overlapping fragments were assembled. Analysis of the assembled sequence revealed that the cloned cDNA molecule encodes a G-protein coupled receptor.

The invention thus relates to a novel GPCR having the deduced amino acid sequence shown in SEQ ID NO 1.

The "12216 receptor polypeptide" or "12216 receptor protein" refers to the polypeptide in SEQ ID NO 1. The term "receptor protein" or "receptor polypeptide", however, further includes the numerous variants described herein, as well as fragments derived from the full length 12216 polypeptide and variants.

15 The present invention thus provides an isolated or purified 12216 receptor polypeptide and variants and fragments thereof.

The 12216 polypeptide is a 373 residue protein exhibiting three main structural domains. The amino terminal extracellular domain is identified to be within residues 1 to about 25 in SEQ ID NO 1. The transmembrane domain is identified to be within residues from about 26 to about 343 in SEQ ID NO 1. The carboxy terminal intracellular domain is identified to be within residues from about 344 to 373 in SEQ ID NO 1. The transmembrane domain contains seven segments that span the membrane. The transmembrane segments are found from about amino acid 26 to about amino acid 48, from about amino acid 59 to about amino acid 83, from about amino acid 98 to about amino acid 119, from about amino acid 137 to about amino acid 156, from about amino acid 187 to about amino acid 204, from about amino acid 287 to about amino acid 308, and from about amino acid 321 to about amino acid 343. Within the region spanning the entire transmembrane domain are three intracellular and three extracellular loops. The three intracellular loops are found from about amino acid 49 to about amino acid 58, from about amino acid 120 to about amino acid 136, and from about amino acid 205 to about amino acid 286. The three extracellular loops are found at from about amino acid 84 to about amino acid 97, from about amino acid 157 to about amino acid 186, and from about amino acid 309 to about amino acid 320.

5 The transmembrane domain includes a GPCR signal transduction signature, TRY, at residues 120-122. The sequence includes an arginine at residue 121, an invariant amino acid in GPCRs.

10 As used herein, a polypeptide is said to be "isolated" or "purified" when it is
15 substantially free of cellular material when it is isolated from recombinant and non-
 recombinant cells, or free of chemical precursors or other chemicals when it is
 chemically synthesized. A polypeptide, however, can be joined to another polypeptide
 with which it is not normally associated in a cell and still be considered "isolated" or
 "purified."

20 The receptor polypeptides can be purified to homogeneity. It is understood,
 however, that preparations in which the polypeptide is not purified to homogeneity are
 useful and considered to contain an isolated form of the polypeptide. The critical feature
 is that the preparation allows for the desired function of the polypeptide, even in the
 presence of considerable amounts of other components. Thus, the invention
 encompasses various degrees of purity.

25 In one embodiment, the language "substantially free of cellular material"
 includes preparations of the receptor polypeptide having less than about 30% (by dry
 weight) other proteins (i.e., contaminating protein), less than about 20% other proteins,
 less than about 10% other proteins, or less than about 5% other proteins. When the
 receptor polypeptide is recombinantly produced, it can also be substantially free of
 culture medium, i.e., culture medium represents less than about 20%, less than about
 10%, or less than about 5% of the volume of the protein preparation.

35 A receptor polypeptide is also considered to be isolated when it is part of a
 membrane preparation or is purified and then reconstituted with membrane vesicles or
 liposomes.

40 The language "substantially free of chemical precursors or other chemicals"
 includes preparations of the receptor polypeptide in which it is separated from chemical
 precursors or other chemicals that are involved in its synthesis. In one embodiment, the
 language "substantially free of chemical precursors or other chemicals" includes
45 preparations of the polypeptide having less than about 30% (by dry weight) chemical
 precursors or other chemicals, less than about 20% chemical precursors or other
 chemicals, less than about 10% chemical precursors or other chemicals, or less than
 about 5% chemical precursors or other chemicals.

5 In one embodiment, the receptor polypeptide comprises the amino acid sequence shown in SEQ ID NO 1. However, the invention also encompasses sequence variants. Variants include a substantially homologous protein encoded by the same genetic locus in an organism, i.e., an allelic variant. The 12216 receptor has been mapped to the X
10 5 chromosome, in proximity to the SHGG-31766 marker. Variants also encompass proteins derived from other genetic loci in an organism, but having substantial homology to the 12216 receptor protein of SEQ ID NO 1. Variants also include proteins substantially homologous to the 12216 receptor protein but derived from another organism, i.e., an ortholog. Variants also include proteins that are substantially
15 10 homologous to the 12216 receptor protein that are produced by chemical synthesis. Variants also include proteins that are substantially homologous to the 12216 receptor protein that are produced by recombinant methods. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

20 As used herein, two proteins (or a region of the proteins) are substantially
25 15 homologous when the amino acid sequences are at least about 55-60%, typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more homologous. A substantially homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence hybridizing to the nucleic acid sequence, or portion thereof, of the sequence shown in
30 20 SEQ ID NO 2 under stringent conditions as more fully described below.

35 To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the reference sequence (e.g., when aligning a second sequence to the amino acid sequences herein having 373
40 25 amino acid residues, preferably at least 100, more preferably at least 120, even more preferably at least 140, and even more preferably at least 370 amino acid residues are aligned). The amino acid residues or nucleotides at corresponding amino acid
45 30 positions or nucleotide positions are then compared. When a position in the first
50 55

5 sequence is occupied by the same amino acid residue or nucleotide as the
corresponding position in the second sequence, then the molecules are identical at that
position (as used herein amino acid or nucleic acid "identity" is equivalent to amino
acid or nucleic acid "homology"). The percent identity between the two sequences is
10 5 a function of the number of identical positions shared by the sequences, taking into
account the number of gaps, and the length of each gap, which need to be introduced
for optimal alignment of the two sequences.

15 The invention also encompasses polypeptides having a lower degree of identity
but having sufficient similarity so as to perform one or more of the same functions

10 performed by the 12216 polypeptide. Similarity is determined by conserved amino acid
substitution. Such substitutions are those that substitute a given amino acid in a
20 polypeptide by another amino acid of like characteristics. Conservative substitutions are
likely to be phenotypically silent. Typically seen as conservative substitutions are the
replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile;
25 15 interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp
and Glu, substitution between the amide residues Asn and Gln, exchange of the basic
residues Lys and Arg and replacements among the aromatic residues Phe, Tyr.

30 Guidance concerning which amino acid changes are likely to be phenotypically silent are
found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

35

40

45

50

55

5

10

15

20

25

30

35

TABLE 1. Conservative Amino Acid Substitutions.

Aromatic	Phenylalanine
	Tryptophan
	Tyrosine
Hydrophobic	Leucine
	Isoleucine
	Valine
Polar	Glutamine
	Asparagine
Basic	Arginine
	Lysine
	Histidine
Acidic	Aspartic Acid
	Glutamic Acid
Small	Alanine
	Serine
	Threonine
	Methionine
	Glycine

The comparison of sequences and determination of percent identity and

5 similarity between two sequences can be accomplished using a mathematical
 40 algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University
 Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W.,
 ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part 1*,
 45 Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence*
 50 *Analysis in Molecular Biology*, von Heijne, G., Academic Press, 1987; and *Sequence*
 55 *Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York,
 1991).

5 A preferred, non-limiting example of such a mathematical algorithm is
described in Karlin *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an
10 algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) as
described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing
15 BLAST and Gapped BLAST programs, the default parameters of the respective
programs (e.g., NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. In one
embodiment, parameters for sequence comparison can be set at score= 100,
wordlength=12, or can be varied (e.g., W=5 or W=20).

10 In a preferred embodiment, the percent identity between two amino acid
sequences is determined using the Needleman *et al.* (1970) (*J. Mol. Biol.* 48:444-453)
20 algorithm which has been incorporated into the GAP program in the GCG software
package (available at <http://www.gcg.com>), using either a BLOSUM 62 matrix or a
PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of
1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between
25 two nucleotide sequences is determined using the GAP program in the GCG software
package (Devereux *et al.* (1984) *Nucleic Acids Res.* 12(1):387) (available at
<http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50,
60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.

30 Another preferred, non-limiting example of a mathematical algorithm utilized
20 for the comparison of sequences is the algorithm of Myers and Miller, CABIOS
(1989). Such an algorithm is incorporated into the ALIGN program (version 2.0)
35 which is part of the CGC sequence alignment software package. When utilizing the
ALIGN program for comparing amino acid sequences, a PAM120 weight residue
table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional
25 algorithms for sequence analysis are known in the art and include ADVANCE and
ADAM as described in Torellis *et al* (1994) *Comput. Appl. Biosci.* 10:3-5; and
40 FASTA described in Pearson *et al.* (1988) *PNAS* 85:2444-8.

45 The protein sequence of the present invention can further be used as a "query
30 sequence" to perform a search against public databases to, for example, identify other
family members or related sequences. Such searches can be performed using the
NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.*
215:403-10. BLAST nucleotide searches can be performed with the NBLAST
50 program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to

5 the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in
10 5 Altschul et al., (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

15 A variant polypeptide can differ in amino acid sequence by one or more substitutions, deletions, insertions, inversions, fusions, and truncations or a combination of any of these.

20 Variant polypeptides can be fully functional or can lack function in one or more activities. Thus, in the present case, variations can affect the function, for example, of one or more of the regions corresponding to ligand binding, membrane association, G-protein binding and signal transduction.

25 15 Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. Functional variants can also contain substitution of similar amino acids which result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

30 20 Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

35 25 As indicated, variants can be naturally-occurring or can be made by recombinant means or chemical synthesis to provide useful and novel characteristics for the receptor 40 30 polypeptide. This includes preventing immunogenicity from pharmaceutical formulations by preventing protein aggregation.

45 30 Useful variations further include alteration of ligand binding characteristics. For example, one embodiment involves a variation at the binding site that results in binding but not release, or slower release, of ligand. A further useful variation at the same sites 45 35 can result in a higher affinity for ligand. Useful variations also include changes that provide for affinity for another ligand. Another useful variation includes one that allows binding but which prevents activation by the ligand. Another useful variation includes 50 40 variation in the transmembrane G-protein-binding/signal transduction domain that

5 provides for reduced or increased binding by the appropriate G-protein or for binding by a different G-protein than the one with which the receptor is normally associated.

10 Another useful variation provides a fusion protein in which one or more domains or subregions is operationally fused to one or more domains or subregions from another G-
15 protein coupled receptor.

5 Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant
10 molecules are then tested for biological activity such as receptor binding or *in vitro*, or *in vitro* proliferative activity. Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.*, *Science* 255:306-312 (1992)).

20 15 Substantial homology can be to the entire nucleic acid or amino acid sequence or to fragments of these sequences.

25 30 The invention thus also includes polypeptide fragments of the 12216 receptor protein. Fragments can be derived from the amino acid sequence shown in SEQ ID NO 1. However, the invention also encompasses fragments of the variants of the 12216
20 receptor protein as described herein.

35 40 As used herein, a fragment comprises at least 6 contiguous amino acids, such as from amino acids 1-35, 36-65, 65-109, 108-128, 128-234, 240-291, and 295-373. The invention encompasses other fragments, however, such as any fragment in the protein greater than 16 amino acids. The fragments to which the invention pertains, however,
45 50 25 are not to be construed as encompassing fragments that may be disclosed prior to the present invention and include all unique non-disclosed fragments. Fragments retain one or more of the biological activities of the protein, for example the ability to bind to a G-protein or ligand, as well as fragments that can be used as an immunogen to generate receptor antibodies.

55 30 Biologically active fragments (peptides which are, for example, 6, 10, 12, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) can comprise a domain or motif, e.g., an extracellular or intracellular domain or loop, one or more transmembrane segments, or parts thereof, G-protein binding site, or GPCR signature.

5 glycosylation sites, cAMP and cGMP-dependent, protein kinase C, and casein kinase II phosphorylation sites, N-myristoylation, and prenylation sites. Such domains or motifs can be identified by computerized homology searching procedures.

10 Possible fragments include, but are not limited to: 1) soluble peptides comprising 5 the entire amino terminal extracellular domain about amino acid 1 to about amino acid 25 of SEQ ID NO 1 or parts thereof; 2) peptides comprising the entire carboxy terminal 15 intracellular domain from about amino acid 344 to amino acid 373 of SEQ ID NO 1 or parts thereof; 3) peptides comprising the region spanning the entire transmembrane domain from about amino acid 26 to amino acid 343; 4) any of the specific 10 transmembrane segments, or parts thereof; 5) any of the three intracellular or three extracellular loops, or parts thereof.

20 Possible fragments include, but are not limited to: 1) soluble peptides comprising the entire amino terminal extracellular domain about amino acid 1 to about amino acid 25 of SEQ ID NO 1, or parts thereof; 2) peptides comprising the entire carboxy terminal 15 intracellular domain from about amino acid 344 to amino acid 373 of SEQ ID NO 1, or parts thereof; 3) peptides comprising the region spanning the entire transmembrane domain from about amino acid 26 to about amino acid 343, or parts thereof; 4) any of the specific 30 transmembrane segments, or parts thereof, from about amino acid 26 to about amino acid 48, from about amino acid 59 to about amino acid 83, from about 20 amino acid 98 to about amino acid 119, from about amino acid 137 to about amino acid 156, from about amino acid 187 to about amino acid 204, from about amino acid 287 to about amino acid 308, and from about amino acid 321 to about amino acid 343; 5) any 35 of the three intracellular or three extracellular loops, or parts thereof, from about amino acid 49 to about amino acid 58, from about amino acid 120 to about amino acid 136, 40 from about amino acid 205 to about amino acid 286, from about amino acid 84 to about amino acid 97, from about amino acid 157 to about amino acid 186, and from about amino acid 309 to about amino acid 320. Fragments further include combinations of the 45 above fragments, such as an amino terminal domain combined with one or more transmembrane segments and the attendant extra or intracellular loops or one or more 30 transmembrane segments, and the attendant intra or extracellular loops, plus the carboxy terminal domain. Thus, any of the above fragments can be combined. Other fragments include the mature protein from about amino acid 6 to 373. Other fragments contain the 50 various functional sites described herein, such as N-glycosylation, cAMP and cGMP-

5 dependent, protein kinase C, and casein kinase II phosphorylation sites, N-myristoylation sites, prenylation sites, and a sequence containing the GPCR signature sequence. Fragments, for example, can extend in one or both directions from the functional site to encompass 5, 10, 15, 20, 30, 40, 50, or up to 100 amino acids. Further,
10 5 fragments can include sub-fragments of the specific domains mentioned above, which sub-fragments retain the function of the domain from which they are derived. These regions can be identified by well-known methods involving computerized analysis.

15 Fragments also include antigenic fragments and specifically those shown to have a high antigenic index in Figure 1.

10 Accordingly, possible fragments include fragments defining a ligand-binding site, fragments defining a glycosylation site, fragments defining membrane association, fragments defining N-myristoylation and prenylation sites, fragments defining interaction with G proteins and signal transduction, and fragments defining cAMP and cGMP-dependent, casein kinase II, and protein kinase C phosphorylation sites. By this
20 15 is intended a discrete fragment that provides the relevant function or allows the relevant function to be identified. In a preferred embodiment, the fragment contains the ligand-binding site.

25 The invention also provides fragments with immunogenic properties. These contain an epitope-bearing portion of the 12216 receptor protein and variants. These 30 20 epitope-bearing peptides are useful to raise antibodies that bind specifically to a receptor polypeptide or region or fragment. These peptides can contain at least 6, 12, at least 14, or between at least about 15 to about 30 amino acids.

35 Non-limiting examples of antigenic polypeptides that can be used to generate antibodies include peptides derived from the amino terminal extracellular domain or any 40 25 of the extracellular loops. Regions having a high antigenicity index are shown in Figure 1. However, intracellularly-made antibodies ("intrabodies") are also encompassed, which would recognize intracellular receptor peptide regions.

45 The receptor polypeptides (including variants and fragments which may have been disclosed prior to the present invention) are useful for biological assays related to 50 30 GPCRs. Such assays involve any of the known GPCR functions or activities or properties useful for diagnosis and treatment of GPCR-related conditions. Figures 5-7 show various normal and abnormal tissues in which the receptor is either highly or differentially expressed. Very high expression has been observed in brain, skeletal

5 muscle, colon, mobilized peripheral blood CD34⁺ cells and human embryonic kidney cell lines. Moderate expression is also seen in a variety of other human tissues as shown in Figure 5. In human cardiovascular tissues, the gene is highly expressed in aorta, aorta with intimal proliferations, diseased heart from patients with congestive heart failure, 10 ischemia, and myopathy. The gene is somewhat differentially expressed in the aorta with intimal proliferations. The gene is highly expressed in diseased hearts relative to normal heart, the diseases being congestive heart failure, ischemia and myopathy. This is shown in Figure 6. Figure 7 shows expression in various monkey cardiovascular tissues. Highest expression occurs in coronary artery, femoral artery and renal artery. 15

10 Positive moderate expression occurs in various other monkey cardiovascular tissues. In Figure 6, the data show that positive moderate expression also occurs in other human cardiovascular tissues. Accordingly, the biological assays relevant to the present invention include, but are not limited to, assays using tissues or cells derived from the tissues in which the gene is positively expressed, particularly highly expressed, and 15 differentially expressed, including but not limited to those shown in Figures 5-7.

20 Accordingly, diagnostic assays and treatment regimens particularly apply to disorders involving these tissues in which the gene is highly expressed, differentially expressed, or even moderately expressed. In human cardiovascular disease, expression of the gene and assays based on detecting or modulating this expression are particularly relevant to 25 congestive heart failure, ischemia and myopathy. Moreover, since the gene is particularly highly expressed in hematopoietic progenitor cells, detection or modulation of the gene is relevant to blood cell development, differentiation and proliferation, and accordingly, to treatment of neutropenia, anemia, and thrombocytopenia. In addition, *in situ* hybridization has shown expression in normal endothelial cells and, in 30 atherosclerosis, expression in other atherogenic cells such as smooth muscle and macrophages, detection or modulation of the gene is relevant to the development of atherosclerosis and, accordingly, to treatment of the disorder.

35

40

45 The epitope-bearing receptor and polypeptides may be produced by any conventional means (Houghten, R.A., *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985)).

50 50 Simultaneous multiple peptide synthesis is described in U.S. Patent No. 4,631,211.

Fragments can be discrete (not fused to other amino acids or polypeptides) or can be within a larger polypeptide. Further, several fragments can be comprised within a single larger polypeptide. In one embodiment a fragment designed for expression in a

5 host can have heterologous pre- and pro-polypeptide regions fused to the amino terminus of the receptor fragment and an additional region fused to the carboxyl terminus of the fragment.

10 The invention thus provides chimeric or fusion proteins. These comprise a
5 receptor protein operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the receptor protein. "Operatively linked" indicates that the receptor protein and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the receptor protein.

15 In one embodiment the fusion protein does not affect receptor function *per se*.
20 For example, the fusion protein can be a GST-fusion protein in which the receptor sequences are fused to the N- or C-terminus of the GST sequences. Other types of fusion proteins include, but are not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL-4 fusions, poly-His fusions and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the
25 purification of recombinant receptor protein. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence. Therefore, in another embodiment, the fusion protein contains a
30 heterologous signal sequence at its N- or C-terminus.

20 EP-A-O 464 533 discloses fusion proteins comprising various portions of immunoglobulin constant regions. The Fc is useful in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). In drug
35 discovery, for example, human proteins have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists. Bennett *et al.* (*J. Mol. Recog.* 8:52-58 (1995)) and Johanson *et al.* (*J. Biol. Chem.* 270, 16:9459-9471 (1995)). Thus, this invention also encompasses soluble fusion proteins containing a receptor polypeptide and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclass (IgG, IgM, IgA, IgE). Preferred as
40 immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. For some uses it is desirable to remove the Fc after the fusion protein has been used for its intended purpose, for example when the
45 fusion protein is to be used as antigen for immunizations. In a particular embodiment,
30

5 the Fc part can be removed in a simple way by a cleavage sequence which is also incorporated and can be cleaved with factor Xa.

10 A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are
15 ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-
20 amplified to generate a chimeric gene sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A receptor protein-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the receptor protein.

25 15 Another form of fusion protein is one that directly affects receptor functions. Accordingly, a receptor polypeptide is encompassed by the present invention in which one or more of the receptor domains (or parts thereof) has been replaced by homologous domains (or parts thereof) from another G-protein coupled receptor or other type of receptor. Accordingly, various permutations are possible. The amino terminal
30 20 extracellular domain, or subregion thereof, (for example, ligand-binding) can be replaced with the domain or subregion from another ligand-binding receptor protein. Alternatively, the entire transmembrane domain, or any of the seven segments or loops, or parts thereof, for example, G-protein-binding/signal transduction, can be replaced. Finally, the carboxy terminal intracellular domain or subregion can be replaced. Thus,
35 25 chimeric receptors can be formed in which one or more of the native domains or subregions has been replaced.

40 The isolated receptor protein can be purified from cells that naturally express it, such as from brain, skeletal muscle, colon, mobilized peripheral blood CD34⁺ cells, human embryonic kidney cell lines, aorta, kidney, and monkey coronary, femoral, and
45 30 renal arterial tissue, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods.

45 In one embodiment, the protein is produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the receptor polypeptide is cloned into an

5 expression vector, the expression vector introduced into a host cell and the protein
expressed in the host cell. The protein can then be isolated from the cells by an
appropriate purification scheme using standard protein purification techniques.

10 Polypeptides often contain amino acids other than the 20 amino acids commonly
5 referred to as the 20 naturally-occurring amino acids. Further, many amino acids,
including the terminal amino acids, may be modified by natural processes, such as
15 processing and other post-translational modifications, or by chemical modification
techniques well known in the art. Common modifications that occur naturally in
polypeptides are described in basic texts, detailed monographs, and the research
10 literature, and they are well known to those of skill in the art.

20 Accordingly, the polypeptides also encompass derivatives or analogs in which a
substituted amino acid residue is not one encoded by the genetic code, in which a
25 substituent group is included, in which the mature polypeptide is fused with another
15 compound, such as a compound to increase the half-life of the polypeptide (for example,
polyethylene glycol), or in which the additional amino acids are fused to the mature
polypeptide, such as a leader or secretory sequence or a sequence for purification of the
mature polypeptide or a pro-protein sequence.

30 Known modifications include, but are not limited to, acetylation, acylation,
ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a
20 heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent
attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol,
35 cross-linking, cyclization, disulfide bond formation, demethylation, formation of
covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation,
gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination,
40 25 methylation, myristylation, oxidation, proteolytic processing, phosphorylation,
prenylation, racemization, selenylation, sulfation, transfer-RNA mediated addition of
amino acids to proteins such as arginylation, and ubiquitination.

45 Such modifications are well-known to those of skill in the art and have been
described in great detail in the scientific literature. Several particularly common
30 modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of
glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described
in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E.
50 Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are

5 available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifert *et al.* (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan *et al.* (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

10 5 As is also well known, polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of post-translation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be
15 10 synthesized by non-translational natural processes and by synthetic methods.

20 15 Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. Blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally-occurring and synthetic polypeptides. For instance, the amino
25 20 terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

30 25 The modifications can be a function of how the protein is made. For recombinant polypeptides, for example, the modifications will be determined by the host cell posttranslational modification capacity and the modification signals in the
35 30 polypeptide amino acid sequence. Accordingly, when glycosylation is desired, a polypeptide should be expressed in a glycosylating host, generally a eukaryotic cell. Insect cells often carry out the same posttranslational glycosylations as mammalian cells and, for this reason, insect cell expression systems have been developed to efficiently
40 35 express mammalian proteins having native patterns of glycosylation. Similar 25 considerations apply to other modifications.

45 The same type of modification may be present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain more than one type of modification.

5

Polypeptide uses

The receptor polypeptides are useful for producing antibodies specific for the 12216 receptor protein, regions, or fragments. Regions having a high antigenicity index score are shown in Figure 1.

10

5 The receptor polypeptides (including variants and fragments which may have been disclosed prior to the present invention) are useful for biological assays related to GPCRs. Such assays involve any of the known GPCR functions or activities or properties useful for diagnosis and treatment of GPCR-related conditions. Figures 5-7 show various normal and abnormal tissues in which the receptor is either highly or

15

10 differentially expressed. Very high expression has been observed in brain, skeletal muscle, colon, mobilized peripheral blood CD34⁺ cells and human embryonic kidney cell lines. Moderate expression is also seen in a variety of other human tissues as shown in Figure 5. In human cardiovascular tissues, the gene is highly expressed in aorta, aorta with intimal proliferations, diseased heart from patients with congestive heart failure, 15 ischemia, and myopathy. The gene is somewhat differentially expressed in the aorta with intimal proliferations. The gene is highly expressed in diseased hearts relative to normal heart, the diseases being congestive heart failure, ischemia and myopathy. This is shown in Figure 6. Figure 7 shows expression in various monkey cardiovascular tissues. Highest expression occurs in coronary artery, femoral artery and renal artery.

20

20 Positive moderate expression occurs in various other monkey cardiovascular tissues. In Figure 6, the data show that positive moderate expression also occurs in other human cardiovascular tissues. Accordingly, the biological assays relevant to the present 25 invention include, but are not limited to, assays using tissues or cells derived from the tissues in which the gene is positively expressed, particularly highly expressed, and

30

25 differentially expressed, including but not limited to those shown in Figures 5-7. Accordingly, diagnostic assays and treatment regimens particularly apply to disorders involving these tissues in which the gene is highly expressed, differentially expressed, or even moderately expressed. In human cardiovascular disease, expression of the gene and assays based on detecting or modulating this expression are particularly relevant to 30 congestive heart failure, ischemia and myopathy. Moreover, since the gene is particularly highly expressed in hematopoietic progenitor cells, detection or modulation of the gene is relevant to blood cell development and differentiation and proliferation, and accordingly, to treatment of neutropenia, anemia, and thrombocytopenia. In

35

40

45

50

55

5 addition, *in situ* hybridization has shown expression in normal endothelial cells and, in atherosclerosis, expression in other atherogenic cells, such as smooth muscle and macrophages. Detection or modulation of the gene is, therefore, relevant to the development of atherosclerosis and, accordingly, to treatment of the disorder.

10 5 The receptor polypeptides are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the receptor protein, as a biopsy or expanded in cell culture. In one embodiment, however, cell-based assays involve recombinant host cells expressing the receptor protein.

15 10 Determining the ability of the test compound to interact with the polypeptide can also comprise determining the ability of the test compound to preferentially bind to the polypeptide as compared to the ability of the ligand, or a biologically active portion thereof, to bind to the polypeptide.

20 15 The polypeptides can be used to identify compounds that modulate receptor activity. Such compounds, for example, can increase or decrease affinity or rate of binding to a known ligand, compete with ligand for binding to the receptor, or displace ligand bound to the receptor. Both 12216 protein and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the receptor. These compounds can be further screened against a functional receptor to determine the effect of the compound on the receptor activity. Compounds can be identified that activate (agonist) or inactivate (antagonist) the receptor to a desired degree. Modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject).

25 20 The receptor polypeptides can be used to screen a compound for the ability to stimulate or inhibit interaction between the receptor protein and a target molecule that normally interacts with the receptor protein. The target can be ligand or a component of the signal pathway with which the receptor protein normally interacts (for example, a G-protein or other interactor involved in cAMP or phosphatidylinositol turnover and/or adenylate cyclase, or phospholipase C activation). The assay includes the steps of 30 30 combining the receptor protein with a candidate compound under conditions that allow the receptor protein or fragment to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the receptor protein and the target, such as any of the

5 associated effects of signal transduction such as G-protein phosphorylation, cyclic AMP or phosphatidylinositol turnover, and adenylate cyclase or phospholipase C activation.

10 Determining the ability of the protein to bind to a target molecule can also be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA). Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIACoreTM). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between 15 biological molecules.

20 The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one- 25 compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer Drug Des.* 12:145).

30 Examples of methods for the synthesis of molecular libraries can be found in the art, for example in DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233. Libraries of compounds 35 may be presented in solution (e.g., Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), 40 bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:1865-1869) or on phage (Scott and Smith 45 (1990) *Science* 249:386-390); (Devlin (1990) *Science* 249:404-406); (Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra*).

5 Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g.,
10 Lam *et al.*, *Nature* 354:82-84 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991)) and
15 combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration
20 amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate,
25 directed phosphopeptide libraries, see, e.g., Songyang *et al.*, *Cell* 72:767-778 (1993)); 3)
30 antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single
35 chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-
40 binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g.,
45 molecules obtained from combinatorial and natural product libraries).

50 One candidate compound is a soluble full-length receptor or fragment that
55 competes for ligand binding. Other candidate compounds include mutant receptors or
60 appropriate fragments containing mutations that affect receptor function and thus
65 compete for ligand. Accordingly, a fragment that competes for ligand, for example with
70 a higher affinity, or a fragment that binds ligand but does not allow release, is
75 encompassed by the invention.

80 The invention provides other end points to identify compounds that modulate
85 (stimulate or inhibit) receptor activity. The assays typically involve an assay of events in
90 the signal transduction pathway that indicate receptor activity. Thus, the expression of
95 genes that are up- or down-regulated in response to the receptor protein dependent signal
100 cascade can be assayed. In one embodiment, the regulatory region of such genes can be
105 operably linked to a marker that is easily detectable, such as luciferase. Alternatively,
110 phosphorylation of the receptor protein, or a receptor protein target, could also be
115 measured.

120 25 Any of the biological or biochemical functions mediated by the receptor can be
125 used as an endpoint assay. These include all of the biochemical or
130 biochemical/biological events described herein, in the references cited herein,
135 incorporated by reference for these endpoint assay targets, and other functions known to
140 those of ordinary skill in the art.

145 30 Binding and/or activating compounds can also be screened by using chimeric
150 receptor proteins in which the amino terminal extracellular domain, or parts thereof, the
155 entire transmembrane domain or subregions, such as any of the seven transmembrane
160 segments or any of the intracellular or extracellular loops and the carboxy terminal

5 intracellular domain, or parts thereof, can be replaced by heterologous domains or
subregions. For example, a G-protein-binding region can be used that interacts with a
different G-protein than that which is recognized by the native receptor. Accordingly, a
different set of signal transduction components is available as an end-point assay for
10 activation. Alternatively, the entire transmembrane portion or subregions (such as
transmembrane segments or intracellular or extracellular loops) can be replaced with the
entire transmembrane portion or subregions specific to a host cell that is different from
the host cell from which the amino terminal extracellular domain and/or the G-protein-
binding region are derived. This allows for assays to be performed in other than the
15 specific host cell from which the receptor is derived. Alternatively, the amino terminal
extracellular domain (and/or other ligand-binding regions) could be replaced by a
domain (and/or other binding region) binding a different ligand, thus, providing an assay
for test compounds that interact with the heterologous amino terminal extracellular
domain (or region) but still cause signal transduction. Finally, activation can be detected
20 by a reporter gene containing an easily detectable coding region operably linked to a
transcriptional regulatory sequence that is part of the native signal transduction pathway.
25

30 The receptor polypeptides are also useful in competition binding assays in
methods designed to discover compounds that interact with the receptor. Thus, a
compound is exposed to a receptor polypeptide under conditions that allow the
35 compound to bind or to otherwise interact with the polypeptide. Soluble receptor
polypeptide is also added to the mixture. If the test compound interacts with the soluble
receptor polypeptide, it decreases the amount of complex formed or activity from the
40 receptor target. This type of assay is particularly useful in cases in which compounds are
sought that interact with specific regions of the receptor. Thus, the soluble polypeptide
45 that competes with the target receptor region is designed to contain peptide sequences
corresponding to the region of interest.

40 To perform cell free drug screening assays, it is desirable to immobilize either
the receptor protein, or fragment, or its target molecule to facilitate separation of
complexes from uncomplexed forms of one or both of the proteins, as well as to
45 accommodate automation of the assay.

50 Techniques for immobilizing proteins on matrices can be used in the drug
screening assays. In one embodiment, a fusion protein can be provided which adds a
domain that allows the protein to be bound to a matrix. For example, glutathione-S-

5 transferase/12216 fusion proteins can be adsorbed onto glutathione sepharose beads
(Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are
then combined with the cell lysates (e.g., 35 S-labeled) and the candidate compound, and
the mixture incubated under conditions conducive to complex formation (e.g., at
10 5 physiological conditions for salt and pH). Following incubation, the beads are washed to
remove any unbound label, and the matrix immobilized and radiolabel determined
directly, or in the supernatant after the complexes are dissociated. Alternatively, the
15 complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of
receptor-binding protein found in the bead fraction quantitated from the gel using
10 standard electrophoretic techniques. For example, either the polypeptide or its target
molecule can be immobilized utilizing conjugation of biotin and streptavidin using
20 techniques well known in the art. Alternatively, antibodies reactive with the protein but
which do not interfere with binding of the protein to its target molecule can be
dermatized to the wells of the plate, and the protein trapped in the wells by antibody
15 conjugation. Preparations of a receptor-binding protein and a candidate compound are
25 incubated in the receptor protein-presenting wells and the amount of complex trapped in
the well can be quantitated. Methods for detecting such complexes, in addition to those
described above for the GST-immobilized complexes, include immunodetection of
30 complexes using antibodies reactive with the receptor protein target molecule, or which
20 are reactive with receptor protein and compete with the target molecule; as well as
enzyme-linked assays which rely on detecting an enzymatic activity associated with the
target molecule.

35 Modulators of receptor protein activity identified according to these drug
screening assays can be used to treat a subject with a disorder mediated by the receptor
40 25 pathway, by treating cells that express the 12216 protein, such as those shown in Figures
5-7 and particularly in cells differentially expressing the protein or highly expressing the
protein. Modulation is particularly relevant accordingly in brain, skeletal muscle, colon,
CD34 $^{+}$ progenitor cells, aorta, and kidney. Particularly relevant disorders include, but
45 30 are not limited to, congestive heart failure, ischemia and myopathy. In view of the fact
that the gene is highly expressed in CD34 $^{+}$ progenitor cells, detection/modulation is
particularly relevant for treating neutropenia, thrombocytopenia or anemia. In view of
the fact that the gene is expressed in several atherogenic cell types, such as smooth
50 35 muscle and macrophage, as well as endothelial cells, detection/modulation is particularly

5 relevant for diagnosing and treating diseases involving atherogenesis, including
atherosclerosis. These methods of treatment include the steps of administering the
modulators of protein activity in a pharmaceutical composition as described herein, to a
subject in need of such treatment.

10 5 Disorders involving the spleen include, but are not limited to, splenomegaly,
including nonspecific acute splenitis, congestive splenomegaly, and splenic infarcts;
neoplasms, congenital anomalies, and rupture. Disorders associated with
splenomegaly include infections, such as nonspecific splenitis, infectious
mononucleosis, tuberculosis, typhoid fever, brucellosis, cytomegalovirus, syphilis,
15 10 malaria, histoplasmosis, toxoplasmosis, kala-azar, trypanosomiasis, schistosomiasis,
leishmaniasis, and echinococcosis; congestive states related to partial hypertension,
such as cirrhosis of the liver, portal or splenic vein thrombosis, and cardiac failure;
lymphohematogenous disorders, such as Hodgkin disease, non-Hodgkin
lymphomas/leukemia, multiple myeloma, myeloproliferative disorders, hemolytic
20 15 anemias, and thrombocytopenic purpura; immunologic-inflammatory conditions, such
as rheumatoid arthritis and systemic lupus erythematosus; storage diseases such as
Gaucher disease, Niemann-Pick disease, and mucopolysaccharidoses; and other
conditions, such as amyloidosis, primary neoplasms and cysts, and secondary
neoplasms.

25 30 Disorders involving the lung include, but are not limited to, congenital
anomalies; atelectasis; diseases of vascular origin, such as pulmonary congestion and
edema, including hemodynamic pulmonary edema and edema caused by
microvascular injury, adult respiratory distress syndrome (diffuse alveolar damage),
pulmonary embolism, hemorrhage, and infarction, and pulmonary hypertension and
35 35 vascular sclerosis; chronic obstructive pulmonary disease, such as emphysema,
chronic bronchitis, bronchial asthma, and bronchiectasis; diffuse interstitial
(infiltrative, restrictive) diseases, such as pneumoconioses, sarcoidosis, idiopathic
pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity
pneumonitis, pulmonary eosinophilia (pulmonary infiltration with eosinophilia),
40 40 30 *Bronchiolitis obliterans*-organizing pneumonia, diffuse pulmonary hemorrhage
syndromes, including Goodpasture syndrome, idiopathic pulmonary hemosiderosis
and other hemorrhagic syndromes, pulmonary involvement in collagen vascular
disorders, and pulmonary alveolar proteinosis; complications of therapies, such as

45 50

5 drug-induced lung disease, radiation-induced lung disease, and lung transplantation; tumors, such as bronchogenic carcinoma, including paraneoplastic syndromes, 10 bronchioloalveolar carcinoma, neuroendocrine tumors, such as bronchial carcinoid, miscellaneous tumors, and metastatic tumors; pathologies of the pleura, including 15 inflammatory pleural effusions, noninflammatory pleural effusions, pneumothorax, and pleural tumors, including solitary fibrous tumors (pleural fibroma) and malignant mesothelioma.

15 Disorders involving the colon include, but are not limited to, congenital anomalies, such as atresia and stenosis, Meckel diverticulum, congenital aganglionic 20 megacolon-Hirschsprung disease; enterocolitis, such as diarrhea and dysentery, infectious enterocolitis, including viral gastroenteritis, bacterial enterocolitis, necrotizing enterocolitis, antibiotic-associated colitis (pseudomembranous colitis), and collagenous and lymphocytic colitis, miscellaneous intestinal inflammatory 25 disorders, including parasites and protozoa, acquired immunodeficiency syndrome, 30 transplantation, drug-induced intestinal injury, radiation enterocolitis, neutropenic colitis (typhlitis), and diversion colitis; idiopathic inflammatory bowel disease, such as Crohn disease and ulcerative colitis; tumors of the colon, such as non-neoplastic polyps, adenomas, familial syndromes, colorectal carcinogenesis, colorectal carcinoma, and carcinoid tumors.

35 Disorders involving the liver include, but are not limited to, hepatic injury; jaundice and cholestasis, such as bilirubin and bile formation; hepatic failure and 40 cirrhosis, such as cirrhosis, portal hypertension, including ascites, portosystemic shunts, and splenomegaly; infectious disorders, such as viral hepatitis, including hepatitis A-E infection and infection by other hepatitis viruses, clinicopathologic 45 syndromes, such as the carrier state, asymptomatic infection, acute viral hepatitis, chronic viral hepatitis, and fulminant hepatitis; autoimmune hepatitis; drug- and toxin-induced liver disease, such as alcoholic liver disease; inborn errors of 50 metabolism and pediatric liver disease, such as hemochromatosis, Wilson disease, α -antitrypsin deficiency, and neonatal hepatitis; intrahepatic biliary tract disease, such as secondary biliary cirrhosis, primary biliary cirrhosis; primary sclerosing cholangitis, and anomalies of the biliary tree; circulatory disorders, such as impaired blood flow into the liver, including hepatic artery compromise and portal vein obstruction and thrombosis, impaired blood flow through the liver, including passive congestion and

5 centrilobular necrosis and peliosis hepatitis, hepatic vein outflow obstruction, including hepatic vein thrombosis (Budd-Chiari syndrome) and veno-occlusive disease; hepatic disease associated with pregnancy, such as preeclampsia and eclampsia, acute fatty liver of pregnancy, and intrahepatic cholestasis of pregnancy; hepatic complications
10 of organ or bone marrow transplantation, such as drug toxicity after bone marrow transplantation, graft-versus-host disease and liver rejection, and nonimmunologic damage to liver allografts; tumors and tumorous conditions, such as nodular hyperplasias, adenomas, and malignant tumors, including primary carcinoma of the liver and metastatic tumors.

15 10 Disorders involving the brain include, but are not limited to, disorders involving neurons, and disorders involving glia, such as astrocytes, oligodendrocytes, ependymal cells, and microglia; cerebral edema, raised intracranial pressure and herniation, and hydrocephalus; malformations and developmental diseases, such as neural tube defects, forebrain anomalies, posterior fossa anomalies, and syringomyelia
20 15 and hydromyelia; perinatal brain injury; cerebrovascular diseases, such as those related to hypoxia, ischemia, and infarction, including hypotension, hypoperfusion, and low-flow states--global cerebral ischemia and focal cerebral ischemia--infarction from obstruction of local blood supply, intracranial hemorrhage, including
25 30 intracerebral (intraparenchymal) hemorrhage, subarachnoid hemorrhage and ruptured berry aneurysms, and vascular malformations, hypertensive cerebrovascular disease, including lacunar infarcts, slit hemorrhages, and hypertensive encephalopathy; infections, such as acute meningitis, including acute pyogenic (bacterial) meningitis and acute aseptic (viral) meningitis, acute focal suppurative infections, including brain abscess, subdural empyema, and extradural abscess, chronic bacterial
35 40 25 meningoencephalitis, including tuberculosis and mycobacterioses, neurosyphilis, and neuroborreliosis (Lyme disease), viral meningoencephalitis, including arthropod-borne (Arbo) viral encephalitis, *Herpes simplex* virus Type 1, *Herpes simplex* virus Type 2, *Varicella-zoster* virus (*Herpes zoster*), cytomegalovirus, poliomyelitis, rabies, and human immunodeficiency virus 1, including HIV-1 meningoencephalitis
45 50 30 (subacute encephalitis), vacuolar myelopathy, AIDS-associated myopathy, peripheral neuropathy, and AIDS in children, progressive multifocal leukoencephalopathy, subacute sclerosing panencephalitis, fungal meningoencephalitis, other infectious diseases of the nervous system; transmissible spongiform encephalopathies (prion

5 diseases); demyelinating diseases, including multiple sclerosis, multiple sclerosis variants, acute disseminated encephalomyelitis and acute necrotizing hemorrhagic encephalomyelitis, and other diseases with demyelination; degenerative diseases, such as degenerative diseases affecting the cerebral cortex, including Alzheimer disease

10 5 and Pick disease, degenerative diseases of basal ganglia and brain stem, including Parkinsonism, idiopathic Parkinson disease (paralysis agitans), progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, including striatonigral degeneration, Shy-Drager syndrome, and olivopontocerebellar atrophy, and Huntington disease; spinocerebellar degenerations, including spinocerebellar

15 10 ataxias, including Friedreich ataxia, and ataxia-telangiectasia, degenerative diseases affecting motor neurons, including amyotrophic lateral sclerosis (motor neuron disease), bulbospinal atrophy (Kennedy syndrome), and spinal muscular atrophy; inborn errors of metabolism, such as leukodystrophies, including Krabbe disease, metachromatic leukodystrophy, adrenoleukodystrophy, Pelizaeus-Merzbacher

20 15 disease, and Canavan disease, mitochondrial encephalomyopathies, including Leigh disease and other mitochondrial encephalomyopathies; toxic and acquired metabolic diseases, including vitamin deficiencies such as thiamine (vitamin B₁) deficiency and vitamin B₁₂ deficiency, neurologic sequelae of metabolic disturbances, including hypoglycemia, hyperglycemia, and hepatic encephalopathy, toxic disorders, including

25 30 20 carbon monoxide, methanol, ethanol, and radiation, including combined methotrexate and radiation-induced injury; tumors, such as gliomas, including astrocytoma, including fibrillary (diffuse) astrocytoma and glioblastoma multiforme, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and brain stem glioma, oligodendrogioma, and ependymoma and related paraventricular mass lesions,

35 25 40 20 neuronal tumors, poorly differentiated neoplasms, including medulloblastoma, other parenchymal tumors, including primary brain lymphoma, germ cell tumors, and pineal parenchymal tumors, meningiomas, metastatic tumors, paraneoplastic syndromes, peripheral nerve sheath tumors, including schwannoma, neurofibroma, and malignant peripheral nerve sheath tumor (malignant schwannoma), and

45 30 50 40 25 neurocutaneous syndromes (phakomatoses), including neurofibromatosis, including Type 1 neurofibromatosis (NF1) and TYPE 2 neurofibromatosis (NF2), tuberous sclerosis, and Von Hippel-Lindau disease.

Disorders involving T-cells include, but are not limited to, cell-mediated hypersensitivity, such as delayed type hypersensitivity and T-cell-mediated cytotoxicity, and transplant rejection; autoimmune diseases, such as systemic lupus erythematosus, Sjögren syndrome, systemic sclerosis, inflammatory myopathies, mixed connective tissue disease, and polyarteritis nodosa and other vasculitides; immunologic deficiency syndromes, including but not limited to, primary immunodeficiencies, such as thymic hypoplasia, severe combined immunodeficiency diseases, and AIDS; leukopenia; reactive (inflammatory) proliferations of white cells, including but not limited to, leukocytosis, acute nonspecific lymphadenitis, and chronic nonspecific lymphadenitis; neoplastic proliferations of white cells, including but not limited to lymphoid neoplasms, such as precursor T-cell neoplasms, such as acute lymphoblastic leukemia/lymphoma, peripheral T-cell and natural killer cell neoplasms that include peripheral T-cell lymphoma, unspecified, adult T-cell leukemia/lymphoma, mycosis fungoides and Sézary syndrome, and Hodgkin disease.

In normal bone marrow, the myelocytic series (polymorphonuclear cells) make up approximately 60% of the cellular elements, and the erythrocytic series, 20-30%. Lymphocytes, monocytes, reticular cells, plasma cells and megakaryocytes together constitute 10-20%. Lymphocytes make up 5-15% of normal adult marrow. In the bone marrow, cell types are add mixed so that precursors of red blood cells (erythroblasts), macrophages (monoblasts), platelets (megakaryocytes), polymorphonuclear leucocytes (myeloblasts), and lymphocytes (lymphoblasts) can be visible in one microscopic field. In addition, stem cells exist for the different cell lineages, as well as a precursor stem cell for the committed progenitor cells of the different lineages. The various types of cells and stages of each would be known to the person of ordinary skill in the art and are found, for example, on page 42 (Figure 2-8) of *Immunology, Immunopathology and Immunity*, Fifth Edition, Sell *et al.* Simon and Schuster (1996), incorporated by reference for its teaching of cell types found in the bone marrow. According, the invention is directed to disorders arising from these cells. These disorders include but are not limited to the following: diseases involving hematopoietic stem cells; committed lymphoid progenitor cells; lymphoid cells including B and T-cells; committed myeloid progenitors, including monocytes, granulocytes, and megakaryocytes; and committed erythroid progenitors. These include but are not limited to the leukemias, including B-lymphoid leukemias, T-

5 lymphoid leukemias, undifferentiated leukemias; erythroleukemia, megakaryoblastic leukemia, monocytic; [leukemias are encompassed with and without differentiation]; chronic and acute lymphoblastic leukemia, chronic and acute lymphocytic leukemia, chronic and acute myelogenous leukemia, lymphoma, myelo dysplastic syndrome,
10 5 chronic and acute myeloid leukemia, myelomonocytic leukemia; chronic and acute myeloblastic leukemia, chronic and acute myelogenous leukemia, chronic and acute promyelocytic leukemia, chronic and acute myelocytic leukemia, hematologic malignancies of monocyte-macrophage lineage, such as juvenile chronic
15 10 myelogenous leukemia; secondary AML, antecedent hematological disorder; refractory anemia; aplastic anemia; reactive cutaneous angioendotheliomatosis; fibrosing disorders involving altered expression in dendritic cells, disorders including systemic sclerosis, E-M syndrome, epidemic toxic oil syndrome, eosinophilic fasciitis
20 20 localized forms of scleroderma, keloid, and fibrosing colonopathy; angiomatoid malignant fibrous histiocytoma; carcinoma, including primary head and neck squamous cell carcinoma; sarcoma, including kaposi's sarcoma; fibroadenoma and phyllodes tumors, including mammary fibroadenoma; stromal tumors; phyllodes tumors, including histiocytoma; erythroblastosis; neurofibromatosis; diseases of the
25 30 15 vascular endothelium; demyelinating, particularly in old lesions; gliosis, vasogenic edema, vascular disease, Alzheimer's and Parkinson's disease; T-cell lymphomas; B-cell lymphomas.

30 Disorders involving the heart, include but are not limited to, heart failure, including but not limited to, cardiac hypertrophy, left-sided heart failure, and right-sided heart failure; ischemic heart disease, including but not limited to angina pectoris, myocardial infarction, chronic ischemic heart disease, and sudden cardiac
35 35 death; hypertensive heart disease, including but not limited to, systemic (left-sided) hypertensive heart disease and pulmonary (right-sided) hypertensive heart disease; valvular heart disease, including but not limited to, valvular degeneration caused by calcification, such as calcific aortic stenosis, calcification of a congenitally bicuspid aortic valve, and mitral annular calcification, and myxomatous degeneration of the
40 40 30 mitral valve (mitral valve prolapse), rheumatic fever and rheumatic heart disease, infective endocarditis, and noninfected vegetations, such as nonbacterial thrombotic endocarditis and endocarditis of systemic lupus erythematosus (Libman-Sacks disease), carcinoid heart disease, and complications of artificial valves; myocardial

50

5 disease, including but not limited to dilated cardiomyopathy, hypertrophic
cardiomyopathy, restrictive cardiomyopathy, and myocarditis; pericardial disease,
including but not limited to, pericardial effusion and hemopericardium and
pericarditis, including acute pericarditis and healed pericarditis, and rheumatoid heart
10 disease; neoplastic heart disease, including but not limited to, primary cardiac tumors,
such as myxoma, lipoma, papillary fibroelastoma, rhabdomyoma, and sarcoma, and
cardiac effects of noncardiac neoplasms; congenital heart disease, including but not
15 limited to, left-to-right shunts--late cyanosis, such as atrial septal defect, ventricular
septal defect, patent ductus arteriosus, and atrioventricular septal defect, right-to-left
20 shunts--early cyanosis, such as tetralogy of fallot, transposition of great arteries,
truncus arteriosus, tricuspid atresia, and total anomalous pulmonary venous
connection, obstructive congenital anomalies, such as coarctation of aorta, pulmonary
stenosis and atresia, and aortic stenosis and atresia, and disorders involving cardiac
transplantation.

25 15 Disorders involving blood vessels include, but are not limited to, responses of
vascular cell walls to injury, such as endothelial dysfunction and endothelial
activation and intimal thickening; vascular diseases including, but not limited to,
congenital anomalies, such as arteriovenous fistula, atherosclerosis, and hypertensive
30 vascular disease, such as hypertension; inflammatory disease--the vasculitides, such
as giant cell (temporal) arteritis, Takayasu arteritis, polyarteritis nodosa (classic),
Kawasaki syndrome (mucocutaneous lymph node syndrome), microscopic
35 polyangiitis (microscopic polyarteritis, hypersensitivity or leukocytoclastic angiitis),
Wegener granulomatosis, thromboangiitis obliterans (Buerger disease), vasculitis
associated with other disorders, and infectious arteritis; Raynaud disease; aneurysms
40 and dissection, such as abdominal aortic aneurysms, syphilitic (luetic) aneurysms, and
aortic dissection (dissecting hematoma); disorders of veins and lymphatics, such as
varicose veins, thrombophlebitis and phlebothrombosis, obstruction of superior vena
cava (superior vena cava syndrome), obstruction of inferior vena cava (inferior vena
45 cava syndrome), and lymphangitis and lymphedema; tumors, including benign tumors
and tumor-like conditions, such as hemangioma, lymphangioma, glomus tumor
(glomangioma), vascular ectasias, and bacillary angiomatosis, and intermediate-grade
(borderline low-grade malignant) tumors, such as Kaposi sarcoma and
50 hemangioendothelioma, and malignant tumors, such as angiosarcoma and

5 hemangiopericytoma; and pathology of therapeutic interventions in vascular disease, such as balloon angioplasty and related techniques and vascular replacement, such as coronary artery bypass graft surgery.

Disorders involving red cells include, but are not limited to, anemias, such as

5 hemolytic anemias, including hereditary spherocytosis, hemolytic disease due to erythrocyte enzyme defects: glucose-6-phosphate dehydrogenase deficiency, sickle cell disease, thalassemia syndromes, paroxysmal nocturnal hemoglobinuria, immunohemolytic anemia, and hemolytic anemia resulting from trauma to red cells; and anemias of diminished erythropoiesis, including megaloblastic anemias, such as 10 anemias of vitamin B12 deficiency: pernicious anemia, and anemia of folate deficiency, iron deficiency anemia, anemia of chronic disease, aplastic anemia, pure red cell aplasia, and other forms of marrow failure.

Disorders involving the thymus include developmental disorders, such as DiGeorge syndrome with thymic hypoplasia or aplasia; thymic cysts; thymic hypoplasia, which involves the appearance of lymphoid follicles within the thymus, creating thymic follicular hyperplasia; and thymomas, including germ cell tumors, lymphomas, Hodgkin disease, and carcinoids. Thymomas can include benign or encapsulated thymoma, and malignant thymoma Type I (invasive thymoma) or Type II, designated thymic carcinoma.

20 Disorders involving B-cells include, but are not limited to precursor B-cell neoplasms, such as lymphoblastic leukemia/lymphoma. Peripheral B-cell neoplasms include, but are not limited to, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, plasma cell neoplasms, multiple myeloma, and related entities, lymphoplasmacytic lymphoma (Waldenström macroglobulinemia), mantle cell lymphoma, marginal zone lymphoma (MALToma), and hairy cell leukemia.

Disorders involving the kidney include, but are not limited to, congenital anomalies including, but not limited to, cystic diseases of the kidney, that include but are not limited to, cystic renal dysplasia, autosomal dominant (adult) polycystic kidney disease, autosomal recessive (childhood) polycystic kidney disease, and cystic diseases of renal medulla, which include, but are not limited to, medullary sponge kidney, and nephronophthisis-uremic medullary cystic disease complex, acquired (dialysis-associated) cystic disease, such as simple cysts; glomerular diseases including

5 pathologies of glomerular injury that include, but are not limited to, in situ immune complex deposition, that includes, but is not limited to, anti-GBM nephritis, Heymann nephritis, and antibodies against planted antigens, circulating immune complex nephritis, antibodies to glomerular cells, cell-mediated immunity in glomerulonephritis, activation
10 of alternative complement pathway, epithelial cell injury, and pathologies involving mediators of glomerular injury including cellular and soluble mediators, acute glomerulonephritis, such as acute proliferative (poststreptococcal, postinfectious) glomerulonephritis, including but not limited to, poststreptococcal glomerulonephritis and nonstreptococcal acute glomerulonephritis, rapidly progressive (crescentic)
15 10 glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis (membranous nephropathy), minimal change disease (lipoid nephrosis), focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, IgA nephropathy (Berger disease), focal proliferative and necrotizing glomerulonephritis (focal glomerulonephritis), hereditary nephritis, including but not limited to, Alport syndrome
20 15 and thin membrane disease (benign familial hematuria), chronic glomerulonephritis, glomerular lesions associated with systemic disease, including but not limited to, systemic lupus erythematosus, Henoch-Schönlein purpura, bacterial endocarditis, diabetic glomerulosclerosis, amyloidosis, fibrillary and immunotactoid glomerulonephritis, and other systemic disorders; diseases affecting tubules and
25 20 interstitium, including acute tubular necrosis and tubulointerstitial nephritis, including but not limited to, pyelonephritis and urinary tract infection, acute pyelonephritis, chronic pyelonephritis and reflux nephropathy, and tubulointerstitial nephritis induced by drugs and toxins, including but not limited to, acute drug-induced interstitial
30 25 nephritis, analgesic abuse nephropathy, nephropathy associated with nonsteroidal anti-inflammatory drugs, and other tubulointerstitial diseases including, but not limited to, urate nephropathy, hypercalcemia and nephrocalcinosis, and multiple myeloma; diseases
35 30 of blood vessels including benign nephrosclerosis, malignant hypertension and accelerated nephrosclerosis, renal artery stenosis, and thrombotic microangiopathies including, but not limited to, classic (childhood) hemolytic-uremic syndrome, adult hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura, idiopathic HUS/TTP, and other vascular disorders including, but not limited to, atherosclerotic ischemic renal disease, atheroembolic renal disease, sickle cell disease nephropathy, diffuse cortical necrosis, and renal infarcts; urinary tract obstruction (obstructive

50

55

5 uropathy); urolithiasis (renal calculi, stones); and tumors of the kidney including, but not limited to, benign tumors, such as renal papillary adenoma, renal fibroma or hamartoma (renomedullary interstitial cell tumor), angiomyolipoma, and oncocytoma, and malignant tumors, including renal cell carcinoma (hypernephroma, adenocarcinoma of kidney), which includes urothelial carcinomas of renal pelvis.

10 Disorders involving the skeletal muscle include tumors such as rhabdomyosarcoma.

15 Disorders related to reduced platelet number, thrombocytopenia, include idiopathic thrombocytopenic purpura, including acute idiopathic thrombocytopenic purpura, drug-induced thrombocytopenia, HIV-associated thrombocytopenia, and 20 thrombotic microangiopathies: thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome.

25 Disorders involving precursor T-cell neoplasms include precursor T lymphoblastic leukemia/lymphoma. Disorders involving peripheral T-cell and natural killer cell neoplasms include T-cell chronic lymphocytic leukemia, large granular lymphocytic leukemia, mycosis fungoides and Sézary syndrome, peripheral T-cell lymphoma, unspecified, angioimmunoblastic T-cell lymphoma, angiocentric lymphoma (NK/T-cell lymphoma⁴⁸), intestinal T-cell lymphoma, adult T-cell leukemia/lymphoma, and anaplastic large cell lymphoma.

30 20 Bone-forming cells include the osteoprogenitor cells, osteoblasts, and osteocytes. The disorders of the bone are complex because they may have an impact on the skeleton during any of its stages of development. Hence, the disorders may have variable manifestations and may involve one, multiple or all bones of the body. Such disorders include, congenital malformations, achondroplasia and thanatophoric 35 25 dwarfism, diseases associated with abnormal matrix such as type 1 collagen disease, osteoporosis, Paget's disease, rickets, osteomalacia, high-turnover osteodystrophy, low-turnover of aplastic disease, osteonecrosis, pyogenic osteomyelitis, tuberculous 40 osteomyelitis, osteoma, osteoid osteoma, osteoblastoma, osteosarcoma, osteochondroma, chondromas, chondroblastoma, chondromyxoid fibroma, 45 30 chondrosarcoma, fibrous cortical defects, fibrous dysplasia, fibrosarcoma, malignant fibrous histiocytoma, Ewing's sarcoma, primitive neuroectodermal tumor, giant cell tumor, and metastatic tumors.

The receptor polypeptides are thus useful for treating a receptor-associated disorder characterized by aberrant expression or activity of a receptor protein. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) expression or activity of the protein. In another embodiment, the method involves administering a protein as therapy to compensate for reduced or aberrant expression or activity of the protein.

Stimulation of protein activity is desirable in situations in which the protein is abnormally downregulated and/or in which increased protein activity is likely to have a beneficial effect. Likewise, inhibition of protein activity is desirable in situations in which the protein is abnormally upregulated and/or in which decreased protein activity is likely to have a beneficial effect. In one example of such a situation, a subject has a disorder characterized by aberrant development or cellular differentiation. In another example of such a situation, the subject has a proliferative disease (e.g., cancer) or a disorder characterized by an aberrant hematopoietic response. In another example of such a situation, it is desirable to achieve tissue regeneration in a subject (e.g., where a subject has undergone brain or spinal cord injury and it is desirable to regenerate neuronal tissue in a regulated manner).

In yet another aspect of the invention, the proteins of the invention can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO 94/10300), to identify other proteins (captured proteins) which bind to or interact with the proteins of the invention and modulate their activity.

The receptor polypeptides also are useful to provide a target for diagnosing a disease or predisposition to disease mediated by the receptor protein, especially in cells/tissues in which the gene is highly or differentially expressed as shown in Figures 5-7, and particularly for treating cardiovascular disease as shown in Figure 6, and also for hematopoietic disorders involving development or proliferation of CD34⁺ cells into the various lineages. Further, since the gene is differentially expressed in atherogenic cells, the polypeptides also provide a target for diagnosing atherosclerosis or predisposition to atherosclerosis mediated by the receptor protein. Accordingly,

5 methods are provided for detecting the presence, or levels of, the receptor protein in a cell, tissue, or organism. The method involves contacting a biological sample with a compound capable of interacting with the receptor protein such that the interaction can be detected.

10 5 One agent for detecting receptor protein is an antibody capable of selectively binding to receptor protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

15 The receptor protein also provides a target for diagnosing active disease, or predisposition to disease, in a patient having a variant receptor protein. Thus, receptor protein can be isolated from a biological sample, assayed for the presence of a genetic mutation that results in aberrant receptor protein. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered receptor activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein.

20 30 *In vitro* techniques for detection of receptor protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. Alternatively, the protein can be detected *in vivo* in a subject by introducing into the subject a labeled anti-receptor antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods which detect the allelic variant of a receptor protein expressed in a subject and methods which detect 25 fragments of a receptor protein in a sample.

35 40 The receptor polypeptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M., *Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996), and 45 30 Linder, M.W., *Clin. Chem.* 43(2):254-266 (1997). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic

5 compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic

10 5 treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic

15 10 polymorphism may lead to allelic protein variants of the receptor protein in which one or more of the receptor functions in one population is different from those in another population. The polypeptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other ligand-binding

20 15 regions that are more or less active in ligand binding, and receptor activation. Accordingly, ligand dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic polypeptides could be identified.

30 30 The receptor polypeptides are also useful for monitoring therapeutic effects 20 during clinical trials and other treatment. Thus, the therapeutic effectiveness of an agent that is designed to increase or decrease gene expression, protein levels or receptor activity can be monitored over the course of treatment using the receptor polypeptides as an end-point target. The monitoring can be, for example, as follows: (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) 35 25 detecting the level of expression or activity of a specified protein in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the protein in the post-administration samples; (v) comparing the level of expression or activity of the protein in the pre-administration sample with the protein in the post-administration 40 30 sample or samples; and (vi) increasing or decreasing the administration of the agent to the subject accordingly.

45 45 The receptor polypeptides are also useful for treating a receptor-associated disorder. Accordingly, methods for treatment include the use of soluble receptor or

5 fragments of the receptor protein that compete for ligand binding. These receptors or fragments can have a higher affinity for the ligand so as to provide effective competition.

10 **Antibodies**

15 5 The invention also provides antibodies that selectively bind to the 12216 receptor protein and its variants and fragments. An antibody is considered to selectively bind, even if it also binds to other proteins that are not substantially homologous with the receptor protein. These other proteins share homology with a fragment or domain of the receptor protein. This conservation in specific regions gives rise to antibodies that bind 10 to both proteins by virtue of the homologous sequence. In this case, it would be understood that antibody binding to the receptor protein is still selective.

20 To generate antibodies, an isolated receptor polypeptide is used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. Either the full-length protein or antigenic peptide 15 fragment can be used. Regions having a high antigenicity index are shown in Figure 1.

25 25 Antibodies are preferably prepared from these regions or from discrete fragments in these regions. However, antibodies can be prepared from any region of the peptide as described herein. A preferred fragment produces an antibody that diminishes or 30 completely prevents ligand-binding. Antibodies can be developed against the entire 20 receptor or portions of the receptor, for example, the intracellular carboxy terminal domain, the amino terminal extracellular domain, the entire transmembrane domain or specific segments, any of the intra or extracellular loops, or any portions of the above. 35 Antibodies may also be developed against specific functional sites, such as the site of ligand-binding, the site of G protein coupling, or sites that are glycosylated, 40 myristoylated, prenylated, or phosphorylated.

45 40 An antigenic fragment will typically comprise at least 6 contiguous amino acid residues. The antigenic peptide can comprise a contiguous sequence of at least 12, at least 14 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, or at least 30 amino acid residues. In one embodiment, fragments correspond 30 to regions that are located on the surface of the protein, e.g., hydrophilic regions.

50 45 These fragments are not to be construed, however, as encompassing any fragments which may be disclosed prior to the invention.

5 Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (e.g. Fab or F(ab')₂) can be used.

10 Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, 10 prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of 15 suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliflone, fluorescein, 15 fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

20 An appropriate immunogenic preparation can be derived from native, 20 recombinantly expressed, protein or chemically synthesized peptides.

25 Antibody Uses

30 The antibodies can be used to isolate a receptor protein by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate 30 the purification of the natural receptor protein from cells and recombinantly produced receptor protein expressed in host cells.

35 The antibodies are useful to detect the presence of receptor protein in cells or tissues to determine the pattern of expression of the receptor among various tissues in an organism and over the course of normal development.

40 The antibodies can be used to detect receptor protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression.

45 The antibodies can be used to assess abnormal tissue distribution or abnormal expression during development.

50 Antibody detection of circulating fragments of the full length receptor protein 30 can be used to identify receptor turnover.

55 Further, the antibodies can be used to assess receptor expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to receptor function. When a disorder is caused by an inappropriate

5 tissue distribution, developmental expression, or level of expression of the receptor protein, the antibody can be prepared against the normal receptor protein. If a disorder is characterized by a specific mutation in the receptor protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant receptor
10 5 protein. However, intracellularly-made antibodies ("intrabodies") are also encompassed, which would recognize intracellular receptor peptide regions.

15 The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Antibodies can be developed against the whole receptor or portions of the receptor, for example, portions of the amino 10 terminal extracellular domain or extracellular loops.

20 The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at 25 correcting receptor expression level or the presence of aberrant receptors and aberrant tissue distribution or developmental expression, antibodies directed against the receptor 15 or relevant fragments can be used to monitor therapeutic efficacy. Antibodies accordingly can be used diagnostically to monitor protein levels in tissue as part of a 25 clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen.

30 Additionally, antibodies are useful in pharmacogenomic analysis. Thus, 20 antibodies prepared against polymorphic receptor proteins can be used to identify individuals that require modified treatment modalities.

35 The antibodies are also useful as diagnostic tools as an immunological marker for aberrant receptor protein analyzed by electrophoretic mobility, isoelectric point, 40 tryptic peptide digest, and other physical assays known to those in the art.

45 The antibodies are also useful for tissue typing. Thus, where a specific receptor protein has been correlated with expression in a specific tissue, antibodies that are 30 specific for this receptor protein can be used to identify a tissue type.

50 The antibodies are also useful in forensic identification. Accordingly, where an individual has been correlated with a specific genetic polymorphism resulting in a 45 specific polymorphic protein, an antibody specific for the polymorphic protein can be used as an aid in identification.

The antibodies are also useful for inhibiting receptor function, for example, 55 blocking ligand binding.

5 These uses can also be applied in a therapeutic context in which treatment involves inhibiting receptor function. An antibody can be used, for example, to block ligand binding. Antibodies can be prepared against specific fragments containing sites required for function or against intact receptor associated with a cell.

10 5 Completely human antibodies are particularly desirable for therapeutic treatment of human patients. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995, *Int. Rev. Immunol.* 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., U.S. Patent 5,625,126; U.S. Patent 5,633,425; U.S. Patent 5,569,825; U.S. Patent 5,661,016; and U.S. Patent 5,545,806.

20 The invention also encompasses kits for using antibodies to detect the presence of a receptor protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting receptor protein in a biological sample; means for determining the amount of receptor protein in the sample; and means for comparing the amount of receptor protein in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect receptor protein.

30 20 **Polynucleotides**

35 The nucleotide sequence in SEQ ID NO 2 was obtained by sequencing a human full length cDNA.

40 The specifically disclosed cDNA comprises the coding region and 5' and 3' untranslated sequences (SEQ ID NO 2).

45 25 The human 12216 receptor cDNA is approximately 2548 nucleotides in length and encodes a full length protein that is approximately 373 amino acid residues in length. Structural analysis of the amino acid sequence of SEQ ID NO 1 is provided in Figure 1, a hydropathy plot. The figure shows the putative structure of the seven transmembrane segments, the amino terminal extracellular domain and the carboxy terminal intracellular domain.

50 30 As used herein, the term "transmembrane segment" refers to a structural amino acid motif which includes a hydrophobic helix that spans the plasma membrane. The entire transmembrane domain spans from about amino acid 26 to about amino acid 343.

5 Seven segments span the membrane and there are three intracellular and three
extracellular loops in this domain.

10 The invention provides isolated polynucleotides encoding a 12216 receptor
protein. The term "12216 polynucleotide" or "12216 nucleic acid" refers to the sequence
15 shown in SEQ ID NO 2. The term "receptor polynucleotide" or "receptor nucleic acid"
further includes variants and fragments of the 12216 polynucleotide.

20 An "isolated" receptor nucleic acid is one that is separated from other nucleic
acid present in the natural source of the receptor nucleic acid. Preferably, an "isolated"
25 nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences
located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism
from which the nucleic acid is derived. However, there can be some flanking nucleotide
30 sequences, for example up to about 5KB. The important point is that the nucleic acid is
isolated from flanking sequences such that it can be subjected to the specific
manipulations described herein such as recombinant expression, preparation of probes
35 and primers, and other uses specific to the receptor nucleic acid sequences.

40 Moreover, an "isolated" nucleic acid molecule, such as a cDNA or RNA
molecule, can be substantially free of other cellular material, or culture medium when
produced by recombinant techniques, or chemical precursors or other chemicals when
chemically synthesized. However, the nucleic acid molecule can be fused to other
45 coding or regulatory sequences and still be considered isolated.

50 For example, recombinant DNA molecules contained in a vector are considered
isolated. Further examples of isolated DNA molecules include recombinant DNA
molecules maintained in heterologous host cells or purified (partially or substantially)
55 DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA
transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid
molecules according to the present invention further include such molecules produced
40 synthetically.

55 In some instances, the isolated material will form part of a composition (for
example, a crude extract containing other substances), buffer system or reagent mix.
45 In other circumstances, the material may be purified to essential homogeneity, for
example as determined by PAGE or column chromatography such as HPLC.
50 Preferably, an isolated nucleic acid comprises at least about 50, 80 or 90 % (on a
molar basis) of all macromolecular species present.

The receptor polynucleotides can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance).

Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

The receptor polynucleotides include, but are not limited to, the sequence 10 encoding the mature polypeptide alone, the sequence encoding the mature polypeptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature polypeptide, with or without the additional coding sequences, plus additional non-coding sequences, for example 15 introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the polynucleotide may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Receptor polynucleotides can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

One receptor nucleic acid comprises the nucleotide sequence shown in SEQ ID NO 2, corresponding to human prostate cDNA.

In one embodiment, the receptor nucleic acid comprises only the coding region. The invention further provides variant receptor polynucleotides, and fragments thereof, that differ from the nucleotide sequence shown in SEQ ID NO 2 due to degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequence shown in SEQ ID NO 2.

The invention also provides receptor nucleic acid molecules encoding the variant polypeptides described herein. Such polynucleotides may be naturally occurring, such as allelic variants (same locus) (maps to the X chromosome near SHGG-31766),

5 homologs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. Accordingly, as discussed above, the variants can
10 5 contain nucleotide substitutions, deletions, inversions and insertions.

Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

15 Typically, variants have a substantial identity with a nucleic acid molecule shown in SEQ ID NO:2 and the complement thereof.

10 Orthologs, homologs, and allelic variants can be identified using methods well known in the art. These variants comprise a nucleotide sequence encoding a receptor that is 55%, at least about 55%, typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more homologous to the nucleotide sequence shown in SEQ ID NO 2 or a fragment of this sequence. Such
20 15 nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions, to the nucleotide sequence shown in SEQ ID NO 2 or a fragment of the sequence. It is understood that stringent hybridization does not indicate substantial homology where it is due to general homology, such as poly A sequences, or sequences common to all or most proteins, all GPCRs, or all family I GPCRs. Moreover, it is
25 20 understood that variants do not include any of the nucleic acid sequences that may have been disclosed prior to the invention.

30 As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a receptor polypeptide at least 50-55%, 55% homologous to each other
35 25 typically remain hybridized to each other. The conditions can be such that sequences at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95% or more identical to each other remain hybridized to one another. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989),
40 30 6.3.1-6.3.6, incorporated by reference. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. In another non-limiting example, nucleic acid molecules are allowed to hybridize in 6X sodium
45 35 50

chloride/sodium citrate (SSC) at about 45°C, followed by one or more low stringency washes in 0.2X SSC/0.1% SDS at room temperature, or by one or more moderate stringency washes in 0.2X SSC/0.1% SDS at 42°C, or washed in 0.2X SSC/0.1% SDS at 65°C for high stringency. In one embodiment, an isolated receptor nucleic acid molecule that hybridizes under stringent conditions to the sequence of SEQ ID NO:2 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

As understood by those of ordinary skill, the exact conditions can be

10 determined empirically and depend on ionic strength, temperature and the
concentration of destabilizing agents such as formamide or denaturing agents such as
SDS. Other factors considered in determining the desired hybridization conditions
include the length of the nucleic acid sequences, base composition, percent mismatch
between the hybridizing sequences and the frequency of occurrence of subsets of the
15 sequences within other non-identical sequences. Thus, equivalent conditions can be
determined by varying one or more of these parameters while maintaining a similar
degree of identity or similarity between the two nucleic acid molecules.

The present invention also provides isolated nucleic acids that contain a single or double stranded fragment or portion that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:2 and the complement of SEQ ID NO:2. In one embodiment, the nucleic acid consists of a portion of the nucleotide sequence of SEQ ID NO:2 or the complement of SEQ ID NO:2. The nucleic acid fragments of the invention are at least about 15, preferably at least about 18, 20, 23 or 25 nucleotides, and can be 30, 40, 50, 100, 200 or more nucleotides in length. Longer fragments, for example, 30 or more nucleotides in length, which encode antigenic proteins or polypeptides described herein are useful.

Furthermore, the invention provides polynucleotides that comprise a fragment of the full length receptor polynucleotides. The fragment can be single or double stranded and can comprise DNA or RNA. The fragment can be derived from either the coding or the non-coding sequence.

It is understood that isolated fragments include any contiguous sequence not disclosed prior to the invention as well as sequences that are substantially the same and which are not disclosed. Accordingly, if a fragment is disclosed prior to the present

5 invention, that fragment is not intended to be encompassed by the present invention. Accordingly, when a sequence is not disclosed prior to the present invention, an isolated receptor nucleic acid fragment is at least about 5, 15, 20, or 30 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the

10 5 nucleotide sequence of SEQ ID NO 2. In other embodiments, the nucleic acid is at least 40, 50, 100, 250 or 500 nucleotides in length. For example, nucleotide sequences 1 to about 360, about 475 to about 800, about 1109 to about 1269, and about 2167 to about 2548 are not disclosed prior to the present invention. Other regions of the nucleotide sequence may comprise fragments of various sizes, depending upon potential homology

15 10 with previous disclosed sequences. For example, the nucleotide sequence from about 360 to about 475 encompasses fragments greater than 81 nucleotides, the nucleotide sequence from about 800 to about 1109 encompasses fragments greater than 15 nucleotides, the nucleotide sequence from about 1269 to about 1498 encompasses fragments greater than 131 nucleotides, the nucleotide sequence from about 1498 to about 1577 encompasses fragments greater than 35 nucleotides, the nucleotide sequence from about 1577 to about 1950 encompasses nucleotide fragments greater than 12, the nucleotide sequence from about 1950 to about 2112 encompasses nucleotide fragments greater than 88, and the nucleotide sequence from about 2108 to about 2167 encompasses nucleotide fragments greater than 32. In these embodiments, depending on

20 15 the region, the nucleic acid can be at least 15, 20, 30, 40, 50, 100, 250, or 500 nucleotides in length or greater. Nucleic acid fragments also include those encoding the receptor polypeptide but extending into the 5' and/or 3' noncoding regions. Further, fragments include parts of the receptor coding region with extensions in the 5' or 3' noncoding sequences.

25 20 In another embodiment an isolated receptor nucleic acid encodes the entire coding region from amino acid 1 to amino acid 373. In another embodiment the isolated receptor nucleic acid encodes a sequence corresponding to the mature protein from about amino acid 6 to amino acid 373. Other fragments include nucleotide sequences encoding the amino acid fragments described herein. Further fragments can include

30 25 subfragments of the specific domains or sites described herein. Fragments also include nucleic acid sequences corresponding to specific amino acid sequences described above or fragments thereof. Nucleic acid fragments, according to the present invention, are not

5 to be construed as encompassing those fragments that may have been disclosed prior to the invention and include all non-disclosed fragments.

10 Receptor nucleic acid fragments further include sequences corresponding to the domains described herein, subregions also described, and specific functional sites.

15 5 Receptor nucleic acid fragments also include combinations of the domains, segments, loops, and other functional sites described above. Thus, for example, a receptor nucleic acid could include sequences corresponding to the amino terminal extracellular domain and one transmembrane fragment. A person of ordinary skill in the art would be aware of the many permutations that are possible.

20 10 Where the location of the domains or sites have been predicted by computer analysis, one of ordinary skill would appreciate that the amino acid residues constituting these domains can vary depending on the criteria used to define the domains.

25 15 However, it is understood that a receptor fragment includes any nucleic acid sequence that does not include the entire gene.

30 20 Receptor nucleic acid fragments include nucleic acid molecules encoding a polypeptide comprising the amino terminal extracellular domain including amino acid residues from 1 to about 25, a polypeptide comprising the region spanning the transmembrane domain (amino acid residues from about 26 to about 343), a polypeptide comprising the carboxy terminal intracellular domain (amino acid residues from about 344 to about 373), and a polypeptide encoding the G-protein receptor signature (120-122 or surrounding amino acid residues from about 110 to about 130), nucleic acid molecules encoding any of the seven transmembrane segments, extracellular or intracellular loops, glycosylation, phosphorylation, myristylation, and prenylation sites. Where the location of the domains have been predicted by computer analysis, one of ordinary skill would appreciate that the amino acid residues constituting these domains can vary depending on the criteria used to define the domains.

35 25 40 The invention also provides receptor nucleic acid fragments that encode epitope bearing regions of the receptor proteins described herein.

40 30 45 The isolated receptor polynucleotide sequences, and especially fragments, are useful as DNA probes and primers.

45 35 50 For example, the coding region of a receptor gene can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate

5 nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of receptor genes.

10 A probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes 15 under stringent conditions to at least about 9, 12, typically about 25, more typically about 40, 50 or 75 consecutive nucleotides of SEQ ID NO 2 sense or anti-sense strand or other receptor polynucleotides. A probe further comprises a label, e.g., radioisotope, fluorescent compound, enzyme, or enzyme co-factor.

15 10 **Polynucleotide Uses**

20 The nucleic acid sequences of the present invention can further be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul *et al.* (1990) *J. 25 Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences 30 homologous to the nucleic acid molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST 20 and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

35 The nucleic acid fragments of the invention provide probes or primers in assays such as those described below. “Probes” are oligonucleotides that hybridize in a base-specific manner to a complementary strand of nucleic acid. Such probes 40 include polypeptide nucleic acids, as described in Nielsen *et al.* (1991) *Science* 254:1497-1500. Typically, a probe comprises a region of nucleotide sequence that hybridizes under highly stringent conditions to at least about 15, typically about 20- 45 25, and more typically about 40, 50 or 75 consecutive nucleotides of the nucleic acid of SEQ ID NO:2 and the complement thereof. More typically, the probe further comprises a label, e.g., radioisotope, fluorescent compound, enzyme, or enzyme co-factor.

50 As used herein, the term “primer” refers to a single-stranded oligonucleotide which acts as a point of initiation of template-directed DNA synthesis using well-

5 known methods (e.g., PCR, LCR) including, but not limited to those described herein. The appropriate length of the primer depends on the particular use, but typically ranges from about 15 to 30 nucleotides. The term "primer site" refers to the area of the target DNA to which a primer hybridizes. The term "primer pair" refers to a set of
10 5 primers including a 5' (upstream) primer that hybridizes with the 5' end of the nucleic acid sequence to be amplified and a 3' (downstream) primer that hybridizes with the complement of the sequence to be amplified.

15 The receptor polynucleotides are useful for probes, primers, and in biological assays.

20 10 Where the polynucleotides are used to assess GPCR properties or functions, such as in the assays described herein, all or less than all of the entire cDNA can be useful. In this case, even fragments that may have been known prior to the invention are encompassed. Thus, for example, assays specifically directed to GPCR functions, such as assessing agonist or antagonist activity, encompass the use of known fragments.

25 15 Further, diagnostic methods for assessing receptor function can also be practiced with any fragment, including those fragments that may have been known prior to the invention. Similarly, in methods involving treatment of receptor dysfunction, all fragments are encompassed including those which may have been known in the art.

30 30 The receptor polynucleotides are useful as a hybridization probe for cDNA and genomic DNA to isolate a full-length cDNA and genomic clones encoding the polypeptide described in SEQ ID NO 1 and to isolate cDNA and genomic clones that correspond to variants producing the same polypeptide shown in SEQ ID NO 1 or the other variants described herein. Variants can be isolated from the same tissue and organism from which the polypeptide shown in SEQ ID NO 1 was isolated, different 35 25 tissues from the same organism, or from different organisms. This method is useful for isolating genes and cDNA that are developmentally-controlled and therefore may be expressed in the same tissue or different tissues at different points in the development of an organism.

40 45 30 The probe can correspond to any sequence along the entire length of the gene encoding the receptor. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. As discussed herein, it is understood that the probe will not correspond to specific fragments that may have been disclosed prior to the 50 present invention but include all fragments that have not been disclosed.

5 The nucleic acid probe can be, for example, the full-length cDNA of SEQ ID NO 1, or a fragment thereof, such as an oligonucleotide of at least 5, 10, 12, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to mRNA or DNA.

10 5 Fragments of the polynucleotides described herein are also useful to synthesize larger fragments or full-length polynucleotides described herein. For example, a fragment can be hybridized to any portion of an mRNA and a larger or full-length cDNA can be produced.

15 10 The fragments are also useful to synthesize antisense molecules of desired length and sequence.

20 20 Antisense nucleic acids of the invention can be designed using the nucleotide sequence of SEQ ID NO:2, and constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using 25 15 naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified 30 30 nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiacytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically 40 40 using an expression vector into which a nucleic acid has been subcloned in an 45 30 50

5 antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest.

10 Additionally, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, 15 hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4:5). As used herein, the 20 terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of 25 PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup *et al.* (1996), *supra*; Perry-O'Keefe *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:14670. 30 PNAs can be further modified, e.g., to enhance their stability, specificity or cellular 35 uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. The synthesis of PNA-DNA chimeras can be performed as 40 described in Hyrup (1996), *supra*; Finn *et al.* (1996) *Nucleic Acids Res.* 24(17):3357- 45 63, Mag *et al.* (1989) *Nucleic Acids Res.* 17:5973, and Peterser *et al.* (1975) *Bioorganic Med. Chem. Lett.* 5:1119.

45 The nucleic acid molecules and fragments of the invention can also include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. WO 88/0918) or the blood brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol *et al.* (1988) *Bio-Techniques* 6:958-976) or intercalating agents (see, e.g., Zon (1988) *Pharm Res.* 5:539-549).

50 The receptor polynucleotides are also useful as primers for PCR to amplify any given region of a receptor polynucleotide.

5 The receptor polynucleotides are also useful for constructing recombinant
vectors. Such vectors include expression vectors that express a portion of, or all of, the
receptor polypeptides. Vectors also include insertion vectors, used to integrate into
another polynucleotide sequence, such as into the cellular genome, to alter *in situ*
10 5 expression of receptor genes and gene products. For example, an endogenous receptor
coding sequence can be replaced via homologous recombination with all or part of the
coding region containing one or more specifically introduced mutations.

15 The receptor polynucleotides are also useful for expressing antigenic portions of
the receptor proteins.

20 10 The receptor polynucleotides are also useful as probes for determining the
chromosomal positions of the receptor polynucleotides by means of *in situ* hybridization
methods, such as FISH (for a review of this technique, see Verma *et al.* (1988) *Human*
25 20 Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York) and PCR
mapping of somatic cell hybrids. The mapping of the sequences to chromosomes is
15 15 an important first step in correlating these sequences with genes associated with
disease.

30 Reagents for chromosome mapping can be used individually to mark a single
chromosome or a single site on that chromosome, or panels of reagents can be used
35 30 for marking multiple sites and/or multiple chromosomes. Reagents corresponding to
20 20 noncoding regions of the genes actually are preferred for mapping purposes. Coding
sequences are more likely to be conserved within gene families, thus increasing the
chance of cross hybridizations during chromosomal mapping.

40 35 Once a sequence has been mapped to a precise chromosomal location, the
physical position of the sequence on the chromosome can be correlated with genetic
45 25 map data. (Such data are found, for example, in V. McKusick, *Mendelian Inheritance*
in Man, available on-line through Johns Hopkins University Welch Medical Library).
The relationship between a gene and a disease, mapped to the same chromosomal
region, can then be identified through linkage analysis (co-inheritance of physically
adjacent genes), described in, for example, Egeland *et al.* (1987) *Nature* 325:783-787.

50 30 Moreover, differences in the DNA sequences between individuals affected and
unaffected with a disease associated with a specified gene, can be determined. If a
mutation is observed in some or all of the affected individuals but not in any
unaffected individuals, then the mutation is likely to be the causative agent of the

5 particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several
10 5 individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

15 The receptor polynucleotide probes are also useful to determine patterns of the presence of the gene encoding the receptors and their variants with respect to tissue distribution, for example, whether gene duplication has occurred and whether the
10 15 duplication occurs in all or only a subset of tissues. The genes can be naturally occurring or can have been introduced into a cell, tissue, or organism exogenously.

20 The receptor polynucleotides are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from genes encoding the polynucleotides described herein.

25 15 The receptor polynucleotides are also useful for constructing host cells expressing a part, or all, of the receptor polynucleotides and polypeptides.

30 The receptor polynucleotides are also useful for constructing transgenic animals expressing all, or a part, of the receptor polynucleotides and polypeptides.

35 20 The receptor polynucleotides are also useful for making vectors that express part, or all, of the receptor polypeptides.

40 35 The receptor polynucleotides are also useful as hybridization probes for determining the level of receptor nucleic acid expression. Accordingly, the probes can be used to detect the presence of, or to determine levels of, receptor nucleic acid in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or
25 40 RNA. Accordingly, probes corresponding to the polypeptides described herein can be used to assess gene copy number in a given cell, tissue, or organism. This is particularly relevant in cases in which there has been an amplification of the receptor genes.

45 30 Alternatively, the probe can be used in an *in situ* hybridization context to assess the position of extra copies of the receptor genes, as on extrachromosomal elements or as integrated into chromosomes in which the receptor gene is not normally found, for example as a homogeneously staining region.

5 These uses are relevant for diagnosis of disorders involving an increase or decrease in receptor expression relative to normal results, such as a proliferative disorder, a differentiative or developmental disorder, or a hematopoietic disorder.

10 Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant expression or activity of receptor nucleic acid, in which a test sample is obtained from a subject and nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of the nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant expression or activity of the nucleic acid.

15 One aspect of the invention relates to diagnostic assays for determining nucleic acid expression as well as activity in the context of a biological sample (e.g., blood, serum, cells, tissue) to determine whether an individual has a disease or disorder, or is at risk of developing a disease or disorder, associated with aberrant nucleic acid expression or activity. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with expression or activity of the nucleic acid molecules.

20 *In vitro* techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA includes Southern hybridizations and *in situ* hybridization.

25 Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a receptor protein, such as by measuring a level of a receptor-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a receptor gene has been mutated.

30 25 Nucleic acid expression assays are useful for drug screening to identify compounds that modulate receptor nucleic acid expression (e.g., antisense, polypeptides, peptidomimetics, small molecules or other drugs). A cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of receptor mRNA in the presence of the candidate compound is compared to the level of expression of receptor mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. The modulator can bind to the nucleic

50

55

5 acid or indirectly modulate expression, such as by interacting with other cellular components that affect nucleic acid expression.

10 5 Modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject) in patients or in transgenic animals.

15 The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the receptor gene. The method typically includes assaying the ability of the compound to modulate the expression of the receptor nucleic acid and thus identifying a compound that can be used 10 to treat a disorder characterized by undesired receptor nucleic acid expression.

20 The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the receptor nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

25 15 Alternatively, candidate compounds can be assayed *in vivo* in patients or in transgenic animals.

30 The assay for receptor nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway (such as cyclic AMP or phosphatidylinositol turnover). Further, the expression 20 of genes that are up- or down-regulated in response to the receptor protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

35 Thus, modulators of receptor gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of receptor mRNA in the presence of the candidate 25 compound is compared to the level of expression of receptor mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its 40 30 absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an 45 inhibitor of nucleic acid expression.

50

5 Accordingly, the invention provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate receptor nucleic acid expression. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or effects 10 5 on nucleic acid activity (e.g., when nucleic acid is mutated or improperly modified). Treatment is of disorders characterized by aberrant expression or activity of the nucleic acid.

15 Alternatively, a modulator for receptor nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the 10 15 drug or small molecule inhibits the receptor nucleic acid expression.

20 The receptor polynucleotides are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the receptor gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with 25 15 compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has 30 20 not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

35 Monitoring can be, for example, as follows: (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a specified mRNA or genomic DNA of the invention in the pre-administration sample; (iii) obtaining one or more post-administration samples from 40 25 the subject; (iv) detecting the level of expression or activity of the mRNA or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the mRNA or genomic DNA in the pre-administration sample with the mRNA or genomic DNA in the post-administration sample or samples; and (vi) increasing or decreasing the administration of the agent to the subject accordingly.

45 The receptor polynucleotides are also useful in diagnostic assays for qualitative 30 changes in receptor nucleic acid, and particularly in qualitative changes that lead to pathology. The polynucleotides can be used to detect mutations in receptor genes and gene expression products such as mRNA. The polynucleotides can be used as 50

5 hybridization probes to detect naturally-occurring genetic mutations in the receptor gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or

10 5 transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the receptor gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a receptor protein.

15 10 Mutations in the receptor gene can be detected at the nucleic acid level by a variety of techniques. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way.

20 15 In certain embodiments, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, *Science* 241:1077-1080 (1988); and Nakazawa *et al.*, *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.*, *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells 25 20 from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a 30 25 control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting 35 30 mutations described herein.

40 45 Alternative amplification methods include: self sustained sequence replication (Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177),

5 Q-Beta Replicase (Lizardi *et al.* (1988) *Bio/Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well-known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are
10 present in very low numbers.

15 Alternatively, mutations in a receptor gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

20 Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

25 Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

30 Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method.

35 Furthermore, sequence differences between a mutant receptor gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT
40 International Publication No. WO 94/16101; Cohen *et al.*, *Adv. Chromatogr.* 36:127-162 (1996); and Griffin *et al.*, *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

45 Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers *et al.*, *Science* 230:1242 (1985)); Cotton *et al.*, *PNAS* 85:4397 (1988); Saleeba *et al.*, *Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.*, *PNAS* 86:2766 (1989); Cotton *et al.*, *Mutat. Res.* 285:125-144 (1993); and Hayashi *et al.*, *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing
50 gradient gel electrophoresis (Myers *et al.*, *Nature* 313:495 (1985)). The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex

5 molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet.* 7:5). Examples of other techniques for detecting point mutations include, selective oligonucleotide hybridization, selective amplification, and selective primer extension.

10 5 In other embodiments, genetic mutations can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotide probes (Cronin *et al.* (1996) *Human Mutation* 7:244-255; Kozal *et al.* (1996) *Nature Medicine* 2:753-759). For example, genetic mutations can be identified in two dimensional arrays containing 10 light-generated DNA probes as described in Cronin *et al. supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the 15 characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

20 30 The receptor polynucleotides are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the polynucleotides can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). In the present case, for example, a mutation 35 in the receptor gene that results in altered affinity for ligand could result in an excessive 25 or decreased drug effect with standard concentrations of ligand that activates the receptor. Accordingly, the receptor polynucleotides described herein can be used to 40 assess the mutation content of the receptor gene in an individual in order to select an appropriate compound or dosage regimen for treatment.

45 30 Thus polynucleotides displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow 45 effective clinical design of treatment compounds and dosage regimens.

5 The methods can involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting mRNA, or genomic DNA, such that the presence of mRNA or genomic DNA is detected in the biological sample, and comparing the presence of mRNA or genomic
10 5 DNA in the control sample with the presence of mRNA or genomic DNA in the test sample.

15 The receptor polynucleotides are also useful for chromosome identification when the sequence is identified with an individual chromosome and to a particular location on the chromosome. First, the DNA sequence is matched to the chromosome by *in situ* or
20 10 other chromosome-specific hybridization. Sequences can also be correlated to specific chromosomes by preparing PCR primers that can be used for PCR screening of somatic cell hybrids containing individual chromosomes from the desired species. Only hybrids containing the chromosome containing the gene homologous to the primer will yield an amplified fragment. Sublocalization can be achieved using chromosomal fragments.
25 15 Other strategies include prescreening with labeled flow-sorted chromosomes and preselection by hybridization to chromosome-specific libraries. Further mapping strategies include fluorescence *in situ* hybridization which allows hybridization with probes shorter than those traditionally used. Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on the chromosome, or
30 20 panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

35 25 The receptor polynucleotides can also be used to identify individuals from small biological samples. This can be done for example using restriction fragment-length polymorphism (RFLP) to identify an individual. Thus, the polynucleotides described herein are useful as DNA markers for RFLP (See U.S. Patent No. 5,272,057).

40 45 Furthermore, the receptor sequence can be used to provide an alternative technique which determines the actual DNA sequence of selected fragments in the genome of an individual. Thus, the receptor sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify DNA from an individual for subsequent sequencing.

50

Panels of corresponding DNA sequences from individuals prepared in this manner can provide unique individual identifications, as each individual will have a unique set of such DNA sequences. It is estimated that allelic variation in humans occurs with a frequency of about once per each 500 bases. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. The receptor sequences can be used to obtain such identification sequences from individuals and from tissue. The sequences represent unique fragments of the human genome. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes.

If a panel of reagents from the sequences is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

The receptor polynucleotides can also be used in forensic identification procedures. PCR technology can be used to amplify DNA sequences taken from very small biological samples, such as a single hair follicle, body fluids (eg. blood, saliva, or semen). The amplified sequence can then be compared to a standard allowing identification of the origin of the sample.

The receptor polynucleotides can thus be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As described above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to the noncoding region are particularly useful since greater polymorphism occurs in the noncoding regions, making it easier to differentiate individuals using this technique. Fragments are at least 5 bases.

30 The receptor polynucleotides can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue. This is useful in cases in which a

5 forensic pathologist is presented with a tissue of unknown origin. Panels of receptor probes can be used to identify tissue by species and/or by organ type.

10 In a similar fashion, these primers and probes can be used to screen tissue culture for contamination (i.e. screen for the presence of a mixture of different types of cells in a 15 culture).

15 Alternatively, the receptor polynucleotides can be used directly to block transcription or translation of receptor gene sequences by means of antisense or ribozyme constructs. Thus, in a disorder characterized by abnormally high or undesirable receptor gene expression, nucleic acids can be directly used for treatment.

20 The receptor polynucleotides are thus useful as antisense constructs to control receptor gene expression in cells, tissues, and organisms. A DNA antisense polynucleotide is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of receptor protein. An antisense RNA or DNA polynucleotide would hybridize to the mRNA and thus block 25 translation of mRNA into receptor protein.

25 Examples of antisense molecules useful to inhibit nucleic acid expression include antisense molecules complementary to a fragment of the 5' untranslated region of SEQ ID NO 2 which also includes the start codon and antisense molecules which are 30 complementary to a fragment of the 3' untranslated region of SEQ ID NO 2.

35 Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of receptor nucleic acid. Accordingly, these molecules can 40 treat a disorder characterized by abnormal or undesired receptor nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability 45 of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the receptor protein, such as ligand binding. These include N-myristylation, prenylation, 50 glycosylation, and phosphorylation sites.

55 The receptor polynucleotides also provide vectors for gene therapy in patients containing cells that are aberrant in receptor gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired receptor protein to treat the individual.

5 The invention also encompasses kits for detecting the presence of a receptor
nucleic acid in a biological sample. For example, the kit can comprise reagents such as a
labeled or labelable nucleic acid or agent capable of detecting receptor nucleic acid in a
biological sample; means for determining the amount of receptor nucleic acid in the
10 sample; and means for comparing the amount of receptor nucleic acid in the sample with
a standard. The compound or agent can be packaged in a suitable container. The kit can
further comprise instructions for using the kit to detect receptor mRNA or DNA.

15 Computer Readable Means

10 The nucleotide or amino acid sequences of the invention are also provided in a
variety of mediums to facilitate use thereof. As used herein, "provided" refers to a
20 manufacture, other than an isolated nucleic acid or amino acid molecule, which
contains a nucleotide or amino acid sequence of the present invention. Such a
manufacture provides the nucleotide or amino acid sequences, or a subset thereof
25 (e.g., a subset of open reading frames (ORFs)) in a form which allows a skilled artisan
to examine the manufacture using means not directly applicable to examining the
nucleotide or amino acid sequences, or a subset thereof, as they exists in nature or in
purified form.

30 In one application of this embodiment, a nucleotide or amino acid sequence of
the present invention can be recorded on computer readable media. As used herein,
20 "computer readable media" refers to any medium that can be read and accessed
directly by a computer. Such media include, but are not limited to: magnetic storage
35 media, such as floppy discs, hard disc storage medium, and magnetic tape; optical
storage media such as CD-ROM; electrical storage media such as RAM and ROM;
40 and hybrids of these categories such as magnetic/optical storage media. The skilled
artisan will readily appreciate how any of the presently known computer readable
mediums can be used to create a manufacture comprising computer readable medium
having recorded thereon a nucleotide or amino acid sequence of the present invention.

45 As used herein, "recorded" refers to a process for storing information on
computer readable medium. The skilled artisan can readily adopt any of the presently
30 known methods for recording information on computer readable medium to generate
manufactures comprising the nucleotide or amino acid sequence information of the
50 present invention.

5 A variety of data storage structures are available to a skilled artisan for
10 creating a computer readable medium having recorded thereon a nucleotide or amino
15 acid sequence of the present invention. The choice of the data storage structure will
20 generally be based on the means chosen to access the stored information. In addition,
25 5 a variety of data processor programs and formats can be used to store the nucleotide
30 sequence information of the present invention on computer readable medium. The
35 sequence information can be represented in a word processing text file, formatted in
40 commercially-available software such as WordPerfect and MicroSoft Word, or
45 represented in the form of an ASCII file, stored in a database application, such as
50 10 DB2, Sybase, Oracle, or the like. The skilled artisan can readily adapt any number of
55 dataprocessor structuring formats (e.g., text file or database) in order to obtain
60 computer readable medium having recorded thereon the nucleotide sequence
65 information of the present invention.

69
70 By providing the nucleotide or amino acid sequences of the invention in
75 computer readable form, the skilled artisan can routinely access the sequence
80 information for a variety of purposes. For example, one skilled in the art can use the
85 nucleotide or amino acid sequences of the invention in computer readable form to
90 compare a target sequence or target structural motif with the sequence information
95 stored within the data storage means. Search means are used to identify fragments or
100 regions of the sequences of the invention which match a particular target sequence or
105 target motif.

110
115 As used herein, a "target sequence" can be any DNA or amino acid sequence
120 of six or more nucleotides or two or more amino acids. A skilled artisan can readily
125 recognize that the longer a target sequence is, the less likely a target sequence will be
130 present as a random occurrence in the database. The most preferred sequence length
135 of a target sequence is from about 10 to 100 amino acids or from about 30 to 300
140 nucleotide residues. However, it is well recognized that commercially important
145 fragments, such as sequence fragments involved in gene expression and protein
150 processing, may be of shorter length.

155
160 As used herein, "a target structural motif," or "target motif," refers to any
165 rationally selected sequence or combination of sequences in which the sequence(s) are
170 chosen based on a three-dimensional configuration which is formed upon the folding
175 of the target motif. There are a variety of target motifs known in the art. Protein

5 target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences).

10 Computer software is publicly available which allows a skilled artisan to 5 access sequence information provided in a computer readable medium for analysis and comparison to other sequences. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. 15 Examples of such software includes, but is not limited to, MacPattern (EMBL), 10 BLASTN and BLASTX (NCBIA).

20 For example, software which implements the BLAST (Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-410) and BLAZE (Brutlag *et al.* (1993) *Comp. Chem.* 17:203-207) 25 search algorithms on a Sybase system can be used to identify open reading frames (ORFs) of the sequences of the invention which contain homology to ORFs or 15 proteins from other libraries. Such ORFs are protein encoding fragments and are useful in producing commercially important proteins such as enzymes used in various reactions and in the production of commercially useful metabolites.

30 Vectors/host cells

20 The invention also provides vectors containing the receptor polynucleotides. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, that can 35 transport the receptor polynucleotides. When the vector is a nucleic acid molecule, the receptor polynucleotides are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a 25 single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

40 A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the receptor polynucleotides. Alternatively, the vector may integrate into the host cell genome and produce additional 45 30 copies of the receptor polynucleotides when the host cell replicates.

45 The invention provides vectors for the maintenance (cloning vectors) or vectors 50 for expression (expression vectors) of the receptor polynucleotides. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

5 Expression vectors contain *cis*-acting regulatory regions that are operably linked
in the vector to the receptor polynucleotides such that transcription of the
polynucleotides is allowed in a host cell. The polynucleotides can be introduced into the
host cell with a separate polynucleotide capable of affecting transcription. Thus, the
10 5 second polynucleotide may provide a *trans*-acting factor interacting with the *cis*-
regulatory control region to allow transcription of the receptor polynucleotides from the
vector. Alternatively, a *trans*-acting factor may be supplied by the host cell. Finally, a
15 trans-acting factor can be produced from the vector itself.

It is understood, however, that in some embodiments, transcription and/or
10 15 translation of the receptor polynucleotides can occur in a cell-free system.

The regulatory sequence to which the polynucleotides described herein can be
20 25 operably linked include promoters for directing mRNA transcription. These include, but
are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC
promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate
15 20 early promoter, the adenovirus early and late promoters, and retrovirus long-terminal
repeats.

In addition to control regions that promote transcription, expression vectors may
30 35 also include regions that modulate transcription, such as repressor binding sites and
enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early
20 25 enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression
35 40 vectors can also contain sequences necessary for transcription termination and, in the
transcribed region a ribosome binding site for translation. Other regulatory control
elements for expression include initiation and termination codons as well as
25 30 polyadenylation signals. The person of ordinary skill in the art would be aware of the
numerous regulatory sequences that are useful in expression vectors. Such regulatory
sequences are described, for example, in Sambrook *et al.*, *Molecular Cloning: A
Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, NY, (1989).

45 50 A variety of expression vectors can be used to express a receptor polynucleotide.
Such vectors include chromosomal, episomal, and virus-derived vectors, for example
vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from
yeast chromosomal elements, including yeast artificial chromosomes, from viruses such

5 as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, eg. cosmids and phagemids. Appropriate cloning and expression
10 5 vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

15 The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell
10 types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression
20 20 in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

25 15 The receptor polynucleotides can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together.
30 Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

35 30 The vector containing the appropriate polynucleotide can be introduced into an appropriate host cell for propagation or expression using well-known techniques.
40 Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

45 45 As described herein, it may be desirable to express the polypeptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the receptor polypeptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that 50 30 the desired polypeptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith *et al.*, *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRITS (Pharmacia, Piscataway, NJ) which

fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, *Gene* 69:301-315 (1988)) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in a host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the polynucleotide of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118 (1992)).

The receptor polynucleotides can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYEpSec1 (Baldari, *et al.*, *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan *et al.*, *Cell* 30:933-943(1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

The receptor polynucleotides can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.*, *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow *et al.*, *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the polynucleotides described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. *Nature* 329:840 (1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the receptor polynucleotides. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the polynucleotides described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring

5 *Harbor Laboratory*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY,
1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the polynucleotide sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

20 The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

25 15 The recombinant host cells are prepared by introducing the vector constructs
described herein into the cells by techniques readily available to the person of ordinary
skill in the art. These include, but are not limited to, calcium phosphate transfection,
DEAE-dextran-mediated transfection, cationic lipid-mediated transfection,
30 20 electroporation, transduction, infection, lipofection, and other techniques such as those
found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold
Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
NY, 1989).

35 Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the
25 receptor polynucleotides can be introduced either alone or with other polynucleotides that are not related to the receptor polynucleotides such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the 40 vectors can be introduced independently, co-introduced or joined to the receptor polynucleotide vector.

45 30 In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which

5 viral replication is defective, replication will occur in host cells providing functions that complement the defects.

10 Vectors generally include selectable markers that enable the selection of the
subpopulation of cells that contain the recombinant vector constructs. The marker can
15 5 be contained in the same vector that contains the polynucleotides described herein or
may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes
for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for
eukaryotic host cells. However, any marker that provides selection for a phenotypic trait
will be effective.

10 While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

25 Where secretion of the polypeptide is desired, appropriate secretion signals are
15 incorporated into the vector. The signal sequence can be endogenous to the receptor
polypeptides or heterologous to these polypeptides.

Where the polypeptide is not secreted into the medium, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The polypeptide can be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

40 25 It is also understood that depending upon the host cell in recombinant production of the polypeptides described herein, the polypeptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the polypeptides may include an initial modified methionine in some cases as a result of a host-mediated process.

5

Uses of vectors and host cells

It is understood that "host cells" and "recombinant host cells" refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

10

5 mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

15

The host cells expressing the polypeptides described herein, and particularly recombinant host cells, have a variety of uses. First, the cells are useful for producing receptor proteins or polypeptides that can be further purified to produce desired amounts 10 of receptor protein or fragments. Thus, host cells containing expression vectors are useful for polypeptide production.

20

Host cells are also useful for conducting cell-based assays involving the receptor or receptor fragments. Thus, a recombinant host cell expressing a native receptor is useful to assay for compounds that stimulate or inhibit receptor function. This includes 15 ligand binding, gene expression at the level of transcription or translation, G-protein interaction, and components of the signal transduction pathway.

25

Host cells are also useful for identifying receptor mutants in which these 30 functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect 20 on the mutant receptor (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native receptor.

35

Recombinant host cells are also useful for expressing the chimeric polypeptides described herein to assess compounds that activate or suppress activation by means of a heterologous amino terminal extracellular domain (or other binding region).

40

25 Alternatively, a heterologous region spanning the entire transmembrane domain (or parts thereof) can be used to assess the effect of a desired amino terminal extracellular domain (or other binding region) on any given host cell. In this embodiment, a region spanning the entire transmembrane domain (or parts thereof) compatible with the specific host cell 40 is used to make the chimeric vector. Alternatively, a heterologous carboxy terminal 30 intracellular, e.g., signal transduction, domain can be introduced into the host cell.

45

Further, mutant receptors can be designed in which one or more of the various 50 functions is engineered to be increased or decreased (e.g., ligand binding or G-protein binding) and used to augment or replace receptor proteins in an individual. Thus, host

5 cells can provide a therapeutic benefit by replacing an aberrant receptor or providing an aberrant receptor that provides a therapeutic result. In one embodiment, the cells provide receptors that are abnormally active.

10 In another embodiment, the cells provide receptors that are abnormally inactive.

15 5 These receptors can compete with endogenous receptors in the individual.

19 In another embodiment, cells expressing receptors that cannot be activated, are introduced into an individual in order to compete with endogenous receptors for ligand. For example, in the case in which excessive ligand is part of a treatment modality, it may be necessary to inactivate this ligand at a specific point in treatment. Providing cells that 10 compete for the ligand, but which cannot be affected by receptor activation would be beneficial.

20 Homologously recombinant host cells can also be produced that allow the *in situ* alteration of endogenous receptor polynucleotide sequences in a host cell genome. The host cell includes, but is not limited to, a stable cell line, cell *in vivo*, or cloned 25 15 microorganism. This technology is more fully described in WO 93/09222, WO 91/12650, WO 91/06667, U.S. 5,272,071, and U.S. 5,641,670. Briefly, specific polynucleotide sequences corresponding to the receptor polynucleotides or sequences proximal or distal to a receptor gene are allowed to integrate into a host cell genome by homologous recombination where expression of the gene can be affected. In one 30 20 embodiment, regulatory sequences are introduced that either increase or decrease expression of an endogenous sequence. Accordingly, a receptor protein can be produced in a cell not normally producing it. Alternatively, increased expression of receptor protein can be effected in a cell normally producing the protein at a specific level.

35 Further, expression can be decreased or eliminated by introducing a specific regulatory 25 25 sequence. The regulatory sequence can be heterologous to the receptor protein sequence or can be a homologous sequence with a desired mutation that affects expression. Alternatively, the entire gene can be deleted. The regulatory sequence can be specific to the host cell or capable of functioning in more than one cell type. Still further, specific 40 30 mutations can be introduced into any desired region of the gene to produce mutant receptor proteins. Such mutations could be introduced, for example, into the specific functional regions such as the ligand-binding site.

45 In one embodiment, the host cell can be a fertilized oocyte or embryonic stem cell that can be used to produce a transgenic animal containing the altered receptor gene.

Alternatively, the host cell can be a stem cell or other early tissue precursor that gives rise to a specific subset of cells and can be used to produce transgenic tissues in an animal. See also Thomas *et al.*, *Cell* 51:503 (1987) for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous receptor gene is selected (see e.g., Li, E. *et al.*, *Cell* 69:915 (1992)). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos. WO 90/11354; WO 91/01140; and WO 93/04169.

The genetically engineered host cells can be used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a receptor protein and identifying and evaluating modulators of receptor protein activity.

Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

In one embodiment, a host cell is a fertilized oocyte or an embryonic stem cell into which receptor polynucleotide sequences have been introduced.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the receptor

5 nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

10 Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation 5 signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the receptor protein to particular cells.

15 Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by 10 Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A 20 transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A 15 transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the 30 homologously recombinant host cells described herein.

20 In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One 35 example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso *et al.* *PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system 25 of *S. cerevisiae* (O'Gorman *et al.* *Science* 251:1351-1355 (1991). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing 40 transgenes encoding both the *Cre* recombinase and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected 45 protein and the other containing a transgene encoding a recombinase.

50 Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al.* *Nature* 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In

5 brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then
10 5 cultured such that it develops to morula or blastocyst and then transferred to a pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

15 Transgenic animals containing recombinant cells that express the polypeptides described herein are useful to conduct the assays described herein in an *in vivo* context.

10 10 Accordingly, the various physiological factors that are present *in vivo* and that could effect ligand binding, receptor activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* receptor function, including ligand interaction, the effect of specific mutant receptors on receptor function and ligand
20 15 interaction, and the effect of chimeric receptors. It is also possible to assess the effect of null mutations, that is mutations that substantially or completely eliminate one or more receptor functions.

25 30 In general, methods for producing transgenic animals include introducing a nucleic acid sequence according to the present invention, the nucleic acid sequence
35 20 capable of expressing the receptor protein in a transgenic animal, into a cell in culture or *in vivo*. When introduced *in vivo*, the nucleic acid is introduced into an intact organism such that one or more cell types and, accordingly, one or more tissue types, express the nucleic acid encoding the receptor protein. Alternatively, the nucleic acid can be introduced into virtually all cells in an organism by transfecting a cell in
40 25 culture, such as an embryonic stem cell, as described herein for the production of transgenic animals, and this cell can be used to produce an entire transgenic organism. As described, in a further embodiment, the host cell can be a fertilized oocyte. Such cells are then allowed to develop in a female foster animal to produce the transgenic organism.

45 30

Pharmaceutical compositions

50 The receptor nucleic acid molecules, protein (particularly fragments such as the amino terminal extracellular domain), modulators of the protein, and antibodies (also

5 referred to herein as "active compounds") can be incorporated into pharmaceutical compositions suitable for administration to a subject, e.g., a human. Such compositions typically comprise the nucleic acid molecule, protein, modulator, or antibody and a pharmaceutically acceptable carrier.

10 5 As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be

15 10 incorporated into the compositions. A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, 15 oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.

20 20 Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants 25 such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be 30 adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The 35 parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose 40 vials made of glass or plastic.

45 25 Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, 30 Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy 45 syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as 50

5 bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance
10 of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the
15 composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

20 Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a receptor protein or anti-receptor antibody) in the required amount in
25 an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred
30 methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

35 Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For oral administration,
40 the agent can be contained in enteric forms to survive the stomach or further coated or mixed to be released in a particular region of the GI tract by known methods. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound
45 in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain
50 any of the following ingredients, or compounds of a similar nature: a binder such as

5 microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, 10 methyl salicylate, or orange flavoring.

15 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

20 Systemic administration can also be by transmucosal or transdermal means. For 10 transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and 25 fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active 15 compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

30 The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

35 In one embodiment, the active compounds are prepared with carriers that will 20 protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.

40 Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, 35 polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.

45 Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova 40 Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled 50 in the art, for example, as described in U.S. Patent No. 4,522,811.

55 It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. "Dosage unit form" as used herein refers to physically discrete units suited as unitary dosages for the

5 subject to be treated; each unit containing a predetermined quantity of active compound
calculated to produce the desired therapeutic effect in association with the required
pharmaceutical carrier. The specification for the dosage unit forms of the invention are
dictated by and directly dependent on the unique characteristics of the active compound
10 and the particular therapeutic effect to be achieved, and the limitations inherent in the art
of compounding such an active compound for the treatment of individuals.

15 The nucleic acid molecules of the invention can be inserted into vectors and used
as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for
example, intravenous injection, local administration (U.S. 5,328,470) or by stereotactic
20 injection (see e.g., Chen *et al.*, *PNAS* 91:3054-3057 (1994)). The pharmaceutical
preparation of the gene therapy vector can include the gene therapy vector in an
acceptable diluent, or can comprise a slow release matrix in which the gene delivery
vehicle is imbedded. Alternatively, where the complete gene delivery vector can be
25 produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical
preparation can include one or more cells which produce the gene delivery system.

30 The pharmaceutical compositions can be included in a container, pack, or
dispenser together with instructions for administration.

35 As defined herein, a therapeutically effective amount of protein or polypeptide
(i.e., an effective dosage) ranges from about 0.001 to 30 mg/kg body weight,
40 preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20
mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to
45 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.

50 The skilled artisan will appreciate that certain factors may influence the
dosage required to effectively treat a subject, including but not limited to the severity
55 of the disease or disorder, previous treatments, the general health and/or age of the
subject, and other diseases present. Moreover, treatment of a subject with a
therapeutically effective amount of a protein, polypeptide, or antibody can include a
40 single treatment or, preferably, can include a series of treatments. In a preferred
example, a subject is treated with antibody, protein, or polypeptide in the range of
between about 0.1 to 20 mg/kg body weight, one time per week for between about 1
55 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7
weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be
appreciated that the effective dosage of antibody, protein, or polypeptide used for

5 treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic assays as described herein.

10 The present invention encompasses agents which modulate expression or 5 activity. An agent may, for example, be a small molecule. For example, such small molecules include, but are not limited to, peptides, peptidomimetics, amino acids, 15 amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and 20 organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a 25 molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

30 15 It is understood that appropriate doses of small molecule agents depends upon 25 a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of the small molecule will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further 35 depending upon the route by which the composition is to be administered, if 40 applicable, and the effect which the practitioner desires the small molecule to have 45 upon the nucleic acid or polypeptide of the invention. Exemplary doses include 50 milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or 55 about 1 microgram per kilogram to about 50 micrograms per kilogram. It is furthermore understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. Such appropriate doses may be determined using the assays described herein. When one or more of these small molecules is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose

5 level for any particular animal subject will depend upon a variety of factors including
the activity of the specific compound employed, the age, body weight, general health,
gender, and diet of the subject, the time of administration, the route of administration,
the rate of excretion, any drug combination, and the degree of expression or activity to
10 be modulated.

15 This invention may be embodied in many different forms and should not be
construed as limited to the embodiments set forth herein; rather, these embodiments are
provided so that this disclosure will fully convey the invention to those skilled in the art.
Many modifications and other embodiments of the invention will come to mind in one
20 skilled in the art to which this invention pertains having the benefit of the teachings
presented in the foregoing description. Although specific terms are employed, they are
used as in the art unless otherwise indicated.

25

30

35

40

45

50

55

Claims

5

10

15

20

THIS PAGE BLANK (USPTO)

25

30

35

40

45

50

55

5

THAT WHICH IS CLAIMED:

1. An isolated polypeptide having an amino acid sequence selected from the group consisting of:

(a) The amino acid sequence shown in SEQ ID NO 1;

(b) The amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO 1;

(c) The amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO 1, wherein the sequence variant is encoded by a nucleic acid molecule hybridizing to the nucleic acid molecule shown in SEQ ID NO 2 under stringent conditions;

(d) A fragment of the amino acid sequence shown in SEQ ID NO 1, wherein the fragment comprises at least 10 contiguous amino acids from 1-238 and 17 contiguous amino acids from 230-373;

(e) The amino acid sequence of the mature receptor polypeptide from about amino acid 6 to about amino acid 373, shown in SEQ ID NO 1;

(f) The amino acid sequence of the polypeptide shown in SEQ ID NO 1, from about amino acid 1 to about amino acid 25; and

(g) The amino acid sequence of an epitope bearing region of any one of the polypeptides of (a)-(f).

20

2. An isolated antibody that selectively binds to a polypeptide of claim 1, (a)-(g).

35

3. An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:

(a) The nucleotide sequence shown in SEQ ID NO 2;

(b) A nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO 1;

(c) A nucleotide sequence complementary to either of the nucleotide

40 30 sequences in (a) or (b).

45 4. An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:

50

55

5 (a) A nucleotide sequence encoding an amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO 1 that hybridizes to the nucleotide sequence shown in SEQ ID NO 2 under stringent conditions; and

10 (b) A nucleotide sequence complementary to the nucleotide sequence in (a).

5 5. An isolated nucleic acid molecule a polynucleotide having a nucleotide sequence selected from the group consisting of:

10 (a) A nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO 1, wherein the fragment comprises at least 10 contiguous amino acids from 1-238 and 17 contiguous amino acids from 230-373; and

15 (b) A nucleotide sequence complementary to the nucleotide sequence in (a).

20 6. A nucleic acid vector comprising the nucleic acid sequences in any of claims 3-5.

25 7. A host cell containing the vector of claim 6.

30 8. A method for producing any of the polypeptides in claim 1 comprising introducing a nucleotide sequence encoding any of the polypeptide sequences in (a)-(g) 20 into a host cell, and culturing the host cell under conditions in which the proteins are expressed from the nucleic acid.

35 9. A method for detecting the presence of any of the polypeptides in claim 1 in a sample, said method comprising contacting said sample with an agent 25 that specifically allows detection of the presence of the polypeptide in the sample and then detecting the presence of the polypeptide.

40 10. The method of claim 9, wherein said agent is capable of selective 45 physical association with said polypeptide.

30 11. The method of claim 10, wherein said agent binds to said polypeptide.

50 12. The method of claim 11, wherein said agent is an antibody.

5

13. The method of claim 11, wherein said agent is a ligand.

10

14. A kit comprising reagents used for the method of claim 9, wherein the
5 reagents comprise an agent that specifically binds to said polypeptide.

15

15. A method for detecting the presence of any of the nucleic acid
molecules in any of claims 3-5 in a sample, the method comprising contacting said
sample with an agent that specifically allows detection of the presence of the nucleic
10 acid molecule in the sample and then detecting the presence of the nucleic acid
molecule.

20

16. The method of claim 15, wherein said method comprises contacting
the sample with an oligonucleotide that hybridizes to the nucleic acid sequences under
15 stringent conditions and determining whether the oligonucleotide binds to the nucleic
acid sequence in the sample.

30

17. The method of claim 15, wherein the nucleic acid, whose presence is
detected, is mRNA.

20

18. A kit comprising reagents used for the method of claim 15, wherein the
reagents comprise a compound that hybridizes under stringent conditions to any of the
35 nucleic acid molecules.

35

25. 19. A method for identifying an agent that interacts with any of the
polypeptides of claim 1 in a cell, said method comprising contacting said agent with a
40 cell capable of allowing an interaction between said polypeptide and said agent such
that said polypeptide can interact with said agent and measuring the interaction.

45

30. 20. A method of screening a cell to identify an agent that interacts with
any of the polypeptides of claim 1 in a cell, said method comprising contacting said
agent with a cell capable of allowing an interaction between said polypeptide and said

50

55

5 agent such that said polypeptide can interact with said agent, and measuring the interaction.

10 21. A method for identifying an agent that binds to any of the polypeptides
5 in claim 1, said method comprising contacting the polypeptide with an agent that
binds to the polypeptide and assaying the complex formed with the agent bound to the
polypeptide.

15 22. The method of claim 21, wherein a fragment of the polypeptide is
10 contacted.

20 23. A method of screening a cell to identify an agent that modulates the
level or activity of any of the polypeptides of claim 1 in a cell, said method
comprising: contacting said agent with a cell capable of expressing said polypeptide
15 such that said polypeptide level or activity can be modulated in said cell by said agent
and measuring said polypeptide level or activity.

25 24. The method of claim 23 wherein said cell is CD34⁺ cell, is derived
from myopathic or ischemic heart tissue, is derived from heart tissue from a subject
20 with congestive heart failure, or an atherogenic cell, such as endothelial, smooth
muscle, or macrophage.

35 25. The method of claim 23 wherein said agent increases the level or
activity of said polypeptide.

40 26. The method of claim 23 wherein said agent decreases the level or
activity of said polypeptide.

45 27. The method of claim 19, said method comprising: (1) exposing said
30 agent to said polypeptide under conditions that allow said agent to interact with said
polypeptide; (2) adding competing polypeptide that can interact with said agent; and
(3) comparing the amount of interaction between said agent and said polypeptide to
50 the amount of interaction in the absence of said competing polypeptide.

5

28. The method of claim 19 wherein said interaction is binding.

10

29. The method of claim 23 wherein said agent increases interaction
5 between said polypeptide and a target molecule for said polypeptide, said method
comprising: combining said polypeptide with said agent under conditions that allow
said polypeptide to interact with said target molecule; and detecting the formation of a
15 complex between said polypeptide and said target molecule or activity of said
polypeptide as a result of interaction of said polypeptide with said target molecule.

15

10

30. The method of claim 23 wherein said agent decreases interaction
20 between said polypeptide and a target molecule for said polypeptide, said method
comprising: combining said polypeptide with said agent under conditions that allow
said polypeptide to interact with said target molecule; and detecting the formation of a
15 complex between said polypeptide and said target molecule or activity of said
polypeptide as a result of interaction of said polypeptide with said target molecule.

25

31. The method of claim 23 wherein said cell is *in vivo*.

30

20

32. The method of claim 31 wherein said cell is in a transgenic animal.

35

33. The method of claim 31 wherein said cell is in a non-transgenic
subject.

40

34. The method of claim 23 wherein said cell is *in vitro*.

45

35. The method of claim 34 wherein said cell has been disrupted.

36. The method of claim 34 wherein said cell is in a biopsy.

50

37. The method of claim 35 wherein said cell is in cell culture.

55

5 38. The method of claim 37 wherein said cell is naturally-occurring or recombinant.

10 5 39. The method of claim 23 wherein said agent is selected from the group consisting of a peptide; phosphopeptide; antibody; organic molecule; and inorganic molecule.

15 10 40. A method for modulating the level or activity of any of the polypeptides of claim 1, said method comprising contacting said polypeptide with an agent under conditions that allow the agent to modulate the level or activity of the polypeptide.

20 15 41. A method for identifying an agent that modulates the level or activity of any of the polypeptides of claim 1 in a cell, said method comprising contacting said agent with a cell capable of expressing said polypeptide such that said polypeptide level or activity can be modulated in said cell by said agent and measuring said polypeptide level or activity.

30 20 42. A method for identifying an agent that modulates the level or activity of any of the nucleic acid molecules of claims 3-5 in a cell, said method comprising contacting said agent with the cell capable of expressing said nucleic acid molecule such that said nucleic acid molecule level or activity can be modulated in said cell by said agent and measuring said nucleic acid molecule level or activity.

35 25 43. A method of screening a cell to identify an agent that modulates the level or activity of any of the nucleic acid molecules in claims 3-5 in said cell, said method comprising contacting said agent with the cell capable of expressing said nucleic acid molecule such that said nucleic acid molecule level or activity can be modulated in said cell by said agent and measuring nucleic acid molecule level or activity.

40 30 44. A method for identifying an agent that interacts with any of the nucleic acid molecules of claims 3-5 in a cell, said method comprising contacting said agent

5 with a cell capable of allowing an interaction between said nucleic acid molecule and said agent such that said nucleic acid molecule can interact with said agent in measuring the interaction.

10 5 45. A method of screening a cell to identify an agent that interacts with
any of the nucleic acid molecules of claims 3-5 in a cell, said method comprising
contacting said agent with a cell capable of allowing an interaction between said
nucleic acid molecule and said agent such that said nucleic acid molecule can interact
15 with said agent and measuring the interaction.

10 46. A method for modulating the level or activity of any of the nucleic acid
20 molecules of claims 3-5, said method comprising contacting said nucleic acid
molecule with an agent under conditions that allow the agent to modulate the level or
activity of the nucleic acid molecule.

48. The method of claim 46 wherein said modulation is *in vivo*.

45 30 50. The method of claim 49 wherein said modulation is in a patient having
or predisposed to having neutropenia, anemia, thrombocytopenia, congestive heart
failure, myopathy, ischemia, or atherosclerosis.

51. A method of treating a disorder selected from the group consisting of neutropenia, anemia, thrombocytopenia, congestive heart failure, myopathy, ischemia,

5 and atherosclerosis in a subject in need of such treatment, said method comprising administering any of the polypeptides of claim 1 to said subject in a therapeutically effective amount.

10 52. A pharmaceutical composition containing any of the polypeptides in claim 1 in a pharmaceutically acceptable carrier.

15 53. A pharmaceutically acceptable composition containing any of the nucleic acid molecules of claims 3-5 in a pharmaceutically acceptable carrier.

10 54. A nonhuman transgenic animal wherein one or more cells of said animal contains any of the nucleic acid sequences of claims 3-5.

15 55. A nonhuman transgenic animal wherein one or more cells of said animal contains any of the nucleic acid sequences of claims 3-5, wherein said cell expresses any of the polypeptides of claim 1.

20 56. A method for producing a transgenic animal according to claim 55, said method comprising introducing any of the nucleic acid sequences of claims 3-5 into a cell, wherein said cell is present in said animal or gives rise to said animal.

30 57. An agent identified by any of the methods of claims 19-39.

35 58. An agent identified by any of the methods of claims 41-45.

40

45

50

55




FIGURE 1

12216orfaa -> KD Hydrophobicity <111>

Protein sequence 374 a.a. MANTGCEPEEV ... APAPREPVCVQ




FIGURE 2

Prosite Pattern Matches for 12216orfaa**Prosite version: Release 12.2 of February 1995****>PS00001|PDOC00001|ASN_GLYCOSYLATION N-glycosylation site.**

Query: 3 NTTG 6
Query: 184 NDTL 187
Query: 229 NWTF 232

>PS00004|PDOC00004|CAMP_PHOSPHO_SITE cAMP- and cGMP-dependent protein kinase phosphorylation

Query: 133 KRMT 136

>PS00005|PDOC00005|PKC_PHOSPHO_SITE Protein kinase C phosphorylation site.

Query: 82 SVR 84
Query: 95 SCK 97
Query: 164 TYK 166
Query: 269 SRR 271

>PS00006|PDOC00006|CK2_PHOSPHO_SITE Casein kinase II phosphorylation site.

Query: 4 TTGE 7

>PS00008|PDOC00008|MYRISTYL N-myristoylation site.

Query: 30 GLIMCV 35
Query: 69 GIRSAV 74
Query: 86 GSSWTF 91
Query: 239 GQAAAN 244
Query: 260 GIRQNG 265

>PS00294|PDOC00266|PRENYLATION Prenyl group binding site (CAAX box).


Query: 371 CVMZ 374

Transmembrane segments for presumed mature peptide

Start	End	Orient	Score
21	45	out-->ins	0.9
60	81	ins-->out	4.9
99	122	out-->ins	3.5
149	166	ins-->out	3.1
207	223	out-->ins	0.1
249	270	ins-->out	5.0
283	305	out-->ins	2.4


>12216orf_{aa}_mature
 GNAISSLVLKERALHKAPYYFLLDCLADGIRSAVCFFPVLASVRHGSSWTFALSCKI
 VAFMAVLFCFCFHAAFMLFCISVTRYMAIAHHRFYAKRMTLWTCAAVICTAWTLSVAMAFPP
 VFDVGTYKFIRGEDQCIFEHRYFKANDTLGFMLMLAVLMAATHAVYGKLLLFYRHRKMK
 PVQMVPASIQNWTFHGPATGQAAANWIAGFGRGPMPPPLLGIQNCHAASRRLLGDEV
 KGEKQLGRMFYATLLFLLWSPYIVACYWRFVKACAVPHRYLATAVWMSFAQAAVNPI
VCFLLNKDLKKCLRTHAPCWGTGGAPAPREPYCVME

FIGURE 4




12216 Expression

FIGURE 5



12216 Expression in Human CV Tissues



12216 Expression in Monkey CV Tissues

SEQUENCE LISTING

<110> Glucksmann, Maria A.

<120> 12216 Receptor, A Novel G-Protein Coupled Receptor

<130> 5800-16A-1

<140>

<141>

<150> 09/200,302

<151> 1998-11-25

<160> 3

<170> PatentIn Ver. 2.0

<210> 1

<211> 373

<212> PRT

<213> Homo sapiens

<400> 1

Met Ala Asn Thr Thr Gly Glu Pro Glu Glu Val Ser Gly Ala Leu Ser
1 5 10 15Pro Pro Ser Ala Ser Ala Tyr Val Lys Leu Val Leu Leu Gly Leu Ile
20 25 30Met Cys Val Ser Leu Ala Gly Asn Ala Ile Leu Ser Leu Leu Val Leu
35 40 45Lys Glu Arg Ala Leu His Lys Ala Pro Tyr Tyr Phe Leu Leu Asp Leu
50 55 60Cys Leu Ala Asp Gly Ile Arg Ser Ala Val Cys Phe Pro Phe Val Leu
65 70 75 80Ala Ser Val Arg His Gly Ser Ser Trp Thr Phe Ser Ala Leu Ser Cys
85 90 95Lys Ile Val Ala Phe Met Ala Val Leu Phe Cys Phe His Ala Ala Phe
100 105 110Met Leu Phe Cys Ile Ser Val Thr Arg Tyr Met Ala Ile Ala His His
115 120 125

Arg Phe Tyr Ala Lys Arg Met Thr Leu Trp Thr Cys Ala Ala Val Ile
130 135 140

Cys Thr Ala Trp Thr Leu Ser Val Ala Met Ala Phe Pro Pro Val Phe
145 150 155 160

Asp Val Gly Thr Tyr Lys Phe Ile Arg Gly Glu Asp Gln Cys Ile Phe
165 170 175

Glu His Arg Tyr Phe Lys Ala Asn Asp Thr Leu Gly Phe Met Leu Met
180 185 190

Leu Ala Val Leu Met Ala Ala Thr His Ala Val Tyr Gly Lys Leu Leu
195 200 205

Leu Phe Glu Tyr Arg His Arg Lys Met Lys Pro Val Gln Met Val Pro
210 215 220

Ala Ile Ser Gln Asn Trp Thr Phe His Gly Pro Gly Ala Thr Gly Gln
225 230 235 240

Ala Ala Ala Asn Trp Ile Ala Gly Phe Gly Arg Gly Pro Met Pro Pro
245 250 255

Thr Leu Leu Gly Ile Arg Gln Asn Gly His Ala Ala Ser Arg Arg Leu
260 265 270

Leu Gly Met Asp Glu Val Lys Gly Glu Lys Gln Leu Gly Arg Met Phe
275 280 285

Tyr Ala Ile Thr Leu Leu Phe Leu Leu Leu Trp Ser Pro Tyr Ile Val
290 295 300

Ala Cys Tyr Trp Arg Val Phe Val Lys Ala Cys Ala Val Pro His Arg
305 310 315 320

Tyr Leu Ala Thr Ala Val Trp Met Ser Phe Ala Gln Ala Ala Val Asn
325 330 335

Pro Ile Val Cys Phe Leu Leu Asn Lys Asp Leu Lys Lys Cys Leu Arg
340 345 350

Thr His Ala Pro Cys Trp Gly Thr Gly Gly Ala Pro Ala Pro Arg Glu
355 360 365

Pro Tyr Cys Val Met
370

```
<210> 2
<211> 2548
<212> DNA
<213> Homo sapiens
```

atgtgcaatg ttgttttagg ccaacccttg ccccaagccc agtctttctt ccctccccac 2520
catgtccaga cctccaaaat ggttcttg 2548

<210> 3
<211> 188
<212> PRT
<213> Unknown

<220>
<223> Description of Unknown Organism: Seven
transmembrane segment rhodopsin superfamily

<400> 3
Gly Asn Leu Leu Val Ile Leu Val Ile Leu Arg Thr Lys Lys Leu Arg
1 5 10 15

Thr Pro Thr Asn Ile Phe Ile Leu Asn Leu Ala Val Ala Asp Leu Leu
20 25 30

Phe Leu Leu Thr Leu Pro Pro Trp Ala Leu Tyr Tyr Leu Val Gly Gly
35 40 45

Ser Glu Asp Trp Pro Phe Gly Ser Ala Leu Cys Lys Leu Val Thr Ala
50 55 60

Leu Asp Val Val Asn Met Tyr Ala Ser Ile Leu Leu Leu Thr Ala Ile
65 70 75 80

Ser Ile Asp Arg Tyr Leu Ala Ile Val His Pro Leu Arg Tyr Arg Arg
85 90 95

Arg Arg Thr Ser Pro Arg Arg Ala Lys Val Val Ile Leu Leu Val Trp
100 105 110

Val Leu Ala Leu Leu Ser Leu Pro Pro Leu Leu Lys Thr Leu Leu
115 120 125

Val Val Val Val Val Phe Val Leu Cys Trp Leu Pro Tyr Phe Ile Val
130 135 140

Leu Leu Leu Asp Thr Leu Cys Leu Ser Ile Ile Met Ser Ser Thr Cys
145 150 155 160

Glu Leu Glu Arg Val Leu Pro Thr Ala Leu Leu Val Thr Leu Trp Leu
165 170 175

Ala Tyr Val Asn Ser Cys Leu Asn Pro Ile Ile Tyr
180 185

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/28090

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C12N15/12	C07K14/72	C07K16/28	G01N33/566	C12Q1/68
	C12N15/11	A61K38/17	A61K31/70	A61K48/00	A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K G01N C12Q A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 55733 A (SMITHKLINE BEECHAM CORP) 4 November 1999 (1999-11-04) the whole document, especially SEQ.IDs. 1 and 2	1-12, 14-39, 41-45, 51-53
P, X	WO 99 46378 A (MATSUMOTO MITSUYUKI ;SAITO TETSU (JP); SUGIMOTO TORU (JP); TAKASAK) 16 September 1999 (1999-09-16) SEQ.IDs. 5 and 6 figure 1	1-12, 14-39, 41-45, 51-53
P, X	WO 99 40100 A (HUMAN GENOME SCIENCES INC ;ROSEN CRAIG A (US); KYAW HLA (US); LAFL) 12 August 1999 (1999-08-12) SEQ.IDs. 13,56 and 62	1-8

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

4 April 2000

Date of mailing of the international search report

25/04/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 MV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

Intell	nal Application No
PCT/US 99/28090	

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ADAMS M. D. ET AL.: "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence." EMBL DATABASE ACCESSION NUMBER AA338949, 21 April 1997 (1997-04-21), XP002134770 abstract	3-5
X	ADAMS M. D. ET AL.: "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence." EMBL DATABASE ACCESSION NUMBER AA359504, 21 April 1997 (1997-04-21), XP002134771 abstract	3-5

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/28090

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 51 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.: 13, 40, 46-50, 57, 58 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

See FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 28090

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 13,40,46-50,57,58

Claims 13, 40, 46-50, 57 and 58 refer to ligands or agents without giving a true technical characterization. Moreover, no such specific ligands or agents are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

Moreover, present claims 9-11 and 14 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to antibodies specific for the G-protein coupled receptor as represented by SEQ.ID.1.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No
PCT/US 99/28090

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9955733	A 04-11-1999	NONE		
WO 9946378	A 16-09-1999	AU 3276699	A 27-09-1999	
WO 9940100	A 12-08-1999	AU 2577799	A 23-08-1999	